

1 **Effects of exercise training on blood pressure:**
2 **an overview of reviews**

3
4 Andrés F. Loaiza-Betancur. *Universidad de Antioquia. Medellín, Colombia. Email:*
5 andres.loaiza@udea.edu.co

6 Lisette Ethel Iglesias Gonzáles. *Fundación Universitaria María Cano, Medellín, Colombia.*
7 *Email: lisetteetheliglesiasgonzalez@fumc.edu.co*

8 Víctor Díaz-López. *Universidad de Antioquia. Medellín, Colombia. Email:*
9 alfonso.diaz@udea.edu.co

10 Andrés M. Echavarría-Rodríguez. *Universidad de Antioquia. Medellín, Colombia. Email:*
11 mauricio.echavarria@udea.edu.co

12 Iván Chulvi-Medrano. *Facultad Ciencias de la Actividad Física y el Deporte. Universidad*
13 *de Valencia. Valencia, España Email: Ivan.Chulvi@uv.es*

14 Edison Andrés Pérez Bedoya. *Universidad de San Buenaventura. Medellín, Colombia.*
15 *Email: edison.bedoya@ufv.br*

16 Luis Andrés Téllez. *Facultad de Cultura Física, Deporte y Recreación. Universidad Santo*
17 *Tomás. Bogotá. Email: luis.tellezt@usantoto.edu.co*

18 Jose F. Meneses-Echavez. *Norwegian Institute of Public Health. Oslo, Norway. Facultad de*
19 *Cultura Física, Deporte y Recreación. Universidad Santo Tomás. Bogotá, Colombia. Email:*
20 jose.meneses@fhi.no

21
22 **Corresponding author:** Jose F. Meneses-Echavez. Division for Health Services.
23 Norwegian Institute of Public Health. Visiting address: Sandakerveien 24C, Building D11,
24 4th floor, office 434. Oslo, Norway.

25 Tel: (+47) 48689405. Email: jose.meneses@fhi.no

26 **ABSTRACT**

27 **BACKGROUND:** This overview of reviews aimed to identify, appraise, and synthesize
28 findings from high-quality systematic reviews on the benefits and harms of different exercise
29 training modalities on blood pressure in adults who either are normotensive, pre-
30 hypertensive, or have high blood pressure.

31 **METHODS:** This review was reported according to the PRISMA Statement. We searched
32 MEDLINE, EMBASE, Epistemonikos, and PROSPERO to identify systematic reviews of
33 randomized controlled trials (RCTs) in adults diagnosed with high blood pressure, other
34 diseases, or cardiovascular risk factors, that compared exercise training with either active
35 interventions or no exercise. Our major outcomes were blood pressure and adverse events.
36 Pairs of reviewers independently screened the systematic reviews for inclusion, extracted
37 data, and appraised the methodological quality. We assessed the certainty of the evidence by
38 using the GRADE approach.

39 **RESULTS:** We included seventeen reviews, who reported on 17 comparisons (290 RCTs; 19
40 232 adults). Any aerobic training probably resulted in a large reduction in SBP in adults with
41 either type II diabetes, metabolic syndrome, end-stage renal disease, or kidney
42 transplantation at short to long-term follow-up (moderate-certainty evidence). Walking
43 aerobic training probably resulted in a large reduction in DBP at short to long-term follow-
44 up in adults with high blood pressure (moderate-certainty evidence). Combined training
45 probably resulted in a large reduction in DBP in adults who either are normotensive, or have
46 high blood pressure, kidney failure, metabolic syndrome, or end-stage renal disease at short
47 to long-term follow-up (moderate-certainty evidence). The body of evidence for the

48 remaining comparisons was rated as low to very low. Eight reviews provided little to no
49 information on safety data.

50 **DISCUSSION:** We found very low to moderate evidence supporting the benefits of exercise
51 training compared with no interventions or placebo for blood pressure in adults with or
52 without comorbidities or risk factors. Scarce safety data were identified. Our certainty in the
53 evidence was downgraded due to methodological limitations, inconsistency, and imprecision.
54 Before drawing more solid conclusions, further well-conducted and well-reported
55 randomized controlled trials are warranted in order to strengthen the evidence base
56 underlying this research question.

57

58 **Protocol registration:** PROSPERO [CRD42021247062](https://www.crd42021247062)

59 **Keywords:** systematic review, meta-analysis, hypertension, exercise training

60

61

62

63

64

65

66

67

68

69 **INTRODUCTION**

70 Cardiovascular diseases (CVDs) represent the third leading cause of death worldwide,
71 counting for 18 million deaths per year (1). Around 10 million people die each year from
72 high blood pressure (HBP), which represents more than half of the mortality attributed to
73 CVDs (2). The economic burden of HBP is high, and the global medical costs of HBP are
74 estimated at 370 billion dollars per year (3,4).

75 Different scientific societies recommend exercise training as part of behavioral change
76 interventions for the prevention and management of HBP (5). Recent clinical guidelines have
77 proposed exercise training as an effective non-pharmacological approach for reducing blood
78 pressure (BP) values at clinically significant levels (reductions in systolic blood pressure
79 ranging between 4 to 8 mmHg) (5). Exercise training has proven to be a safe intervention in
80 CVD patients, since it has been related to fewer adverse effects than either pharmacological
81 or surgical treatments (6). However, the evidence for safety data in patients with HBP
82 remains unclear (6).

83 A recent overview of reviews conducted by researchers from the American College of Sports
84 Medicine (ACSM) concluded that any form of physical activity (PA) reduced BP values in
85 normotensive, pre-hypertensive, and HBP adults (7). The authors summarized data from both
86 exercise training and physical activity into the same analysis, which increased the
87 heterogeneity of their results as evidenced in the analyses. This limitation in the current
88 evidence was further reinforced by incomplete literature searches, as acknowledged recently
89 by European experts in the field (8).

90 The number of systematic reviews (reviews) on the effects of exercise training for HBP has
91 increased exponentially in recent years. Most of those reviews have serious methodological

92 limitations, report heterogeneous effect estimates, and lack systematic assessments of the
93 quality of the evidence(9–11). Considering this, we propose a systematic overview of high-
94 quality systematic reviews with a transparent approach to grade the quality of the evidence
95 in order to facilitate the translation of research findings into practice.

96 **OBJECTIVES**

97 This overview of reviews aims to identify, appraise, and synthesize findings from high-
98 quality systematic reviews on the benefits and harms of different exercise training modalities
99 on blood pressure in adults who either are normotensive, pre-hypertensive, or have high
100 blood pressure.

101 **METHODS**

102 We registered the review protocol in the International Prospective Register of Systematic
103 Reviews (PROSPERO registration number: CRD42021247062 and [Open science](#)
104 [framework](#)), and followed both the methodological guidance provided in Chapter V of the
105 Cochrane handbook version 6.2 (12) and the Preferred Reporting Items for Systematic
106 Reviews and Meta-Analyses (PRISMA) (13,14). For quality purposes, pairs of independent
107 reviewers conducted the following steps: study selection, data extraction, quality appraisal,
108 and assessment of the certainty of the evidence. Disagreements were resolved by consensus
109 or by including a third reviewer if necessary. Additional file 1 provides details on the
110 PRISMA statement.

111 **Eligibility criteria**

112 We used the PICOTS acronym (P - population; I - intervention; C - comparison or control;
113 O- outcome(s), T - Time and S - study design) to guide study selection (15), as follows:

114 **Participants**

115 Adults (≥ 18 years old) with normal, pre-hypertensive, or HBP values, with or without
116 associated risk factors or comorbidities, categorized according to American Heart
117 Association (AHA) criteria (16):

- 118 • Normal: Systolic blood pressure (SBP) <120 mm Hg and diastolic blood pressure
119 (DBP) <80 mm Hg.
- 120 • Pre-hypertensive: SBP 120–129 mm Hg and DBP <80 mm Hg.
- 121 • High blood pressure: SBP 130–139 mm Hg or DBP 80-89 mm Hg.

122

123 **Interventions**

124 We accepted for inclusion different exercise training modalities, such as dynamic resistance
125 training (DRT), isometric resistance training (IRT), aerobic exercise training (AET), and
126 combined training (CT) (5). Figure 1 presents the definitions of the exercise interventions
127 considered for inclusion.

128 **Figure 1.** Definitions of the different exercise training modalities.

Exercise training: Exercise is defined as a planned, structured, repetitive PA aiming to improve or maintain one or more components of physical fitness (i.e., cardiorespiratory fitness and/or muscular fitness) (17). Thus, any PA program which is structured according to parameters and characteristics of Frequency, Intensity, Time, Type, Volume, and Progression) (FITT-VP) was considered as exercise training; otherwise, these programs were discarded.

Dynamic resistance training (DRT): DRT involves an exercise movement using a constant load or a uniform weight regardless of the training program (18).

Isometric resistance training (IRT): IRT is understood as any muscular contraction in which the tension of both the joint and the contractile elements does not vary on the movement range (holding a position or weight without moving against it) (19).

Aerobic training (AET): Cyclic exercises involve a large amount of muscle mass for different time units, where the cardiovascular and respiratory systems predominate (e.g., jogging, swimming, running, cycling, dancing) (18).

Combined training (CT): This training modality represents the systematic integration of both resistance and aerobic exercise within a coherent training plan (20).

129

130 We excluded reviews summarizing evidence from PA programs. PA is defined as any
131 movement of the body generated by the skeletal muscles which generate an energy
132 expenditure (18). However, any PA program which is structured according to the parameters
133 and characteristics of FITT-VP would be considered as exercise training; otherwise, these
134 programs were discarded. A threshold of $\geq 50\%$ primary studies reporting on exercise
135 training were accepted for inclusion. We excluded reviews that focused on pregnant women.

136 **Comparators**

137 Standard care (e.g., pharmacological interventions or behavioral change approaches) or any
138 active intervention (e.g., flexibility, yoga, Qigong), waitlist, or no intervention.

139 **Primary outcomes**

140 **Blood pressure**

141 SBP, DBP, and mean blood pressure (MBP). BP is defined as the force exerted by the
142 circulating blood through the arteries against the arterial wall (21), and includes two
143 measurements: systolic pressure, which is measured during the heartbeat (maximum pressure

144 moment), and diastolic pressure, which is measured during the rest between two beats
145 (minimum pressure moment). Mean blood pressure (MBP), represents the average blood
146 pressure in the arteries is approximately one-third of the way between the diastolic and
147 systolic pressures (21).

148 **Secondary outcome**

149 **Adverse events**

150 The National Institute for Health and Care Excellence (NICE) defines adverse events as any
151 undesirable event experienced by a person while they are having a drug or any other treatment
152 or intervention, regardless of whether the event is suspected to be related to or caused by the
153 drug, treatment or intervention (22).

154 **Time:** Both primary and secondary research studies have reported both clinically and
155 statistically significant effects of the different exercise training modalities on SBP, DBP, and
156 MBP values over a 3-weeks follow-up (23). Therefore, we included reviews reporting
157 outcome data at/over 3 weeks post-intervention follow-up.

158 **Study design:** We included reviews of randomized controlled trials (RCTs) (15,22).
159 Inclusion was restricted to reviews of high methodological quality , which was appraised by
160 using the Assessment of Multiple Systematic Reviews (AMSTAR) tool (24). In terms of the
161 included trials, we included reviews of both randomized and non-randomized studies as long
162 as the review provides separate information for the RCTs (e.g., subgroup data).

163 **Language:** No restrictions were set for language.

164 **Information sources and search strategy**

165 We searched MEDLINE (via Pubmed), EMBASE, and Epistemonikos from inception date
166 to February 02, 2021. No restrictions were applied for the publication date. The search
167 strategy used in MEDLINE is available in the protocol (25); this was tailored to the other
168 databases. Furthermore, one reviewer (AFL-B) inspected the PROSPERO repository for
169 ongoing reviews, the reference lists of the included reviews, as well as the references of
170 clinical guidelines and scientific journals specialized in the field (e.g., Journal of
171 Hypertension).

172 **Study selection process**

173 Two blinded and independent reviewers (AFL-B and EP-B) selected the studies at title,
174 abstract and full-text. These steps were carried out in Rayyan (26).

175 **Data management and extraction**

176 We extracted data from the included reviews into an ad-hoc standardized electronic form
177 created in Google forms (<https://docs.google.com/forms/>). All reviewers piloted this form in
178 a random sample of two reviews (25). If necessary, we tried to contact the corresponding
179 author of the reviews to clarify data or obtain missing information.

180 **Quality appraisal**

181 Pairs of reviewers independently appraised the methodological quality of the included
182 reviews by using the AMSTAR tool (24). AMSTAR is the most widely used tool for critically
183 appraising reviews of RCTs and contains 11 questions, this information is available in the
184 protocol (25). Each question of AMSTAR is rated as yes (clearly done), no (clearly not done),

185 cannot answer, or not applicable (24). In case any of the reviewers participated as an author
186 in an included review, we acknowledged this and allocated the reviews to another reviewer.

187 **Data synthesis**

188 In line with the methodological literature, we propose a narrative synthesis approach for this
189 study (12). We presented data from each review, sorted by each primary and secondary
190 outcome according to the certainty of the evidence (e.g., high-certainty evidence first,
191 followed by moderate-certainty evidence, etc.), follow-up periods, number of participants,
192 and RCTs. Where possible, we presented effect measures mean difference (MD), standard
193 means difference (SMD), relative risk (RR), and odds ratio (OR) with 95% CIs for both
194 continuous and dichotomized outcome measures. We presented the overall results in
195 'Summary of findings' tables (12), according to the following subgroups:

- 196 • The clinical status of the participants regarding AHA (16) blood pressure values:
197 normal, pre-hypertensive, and high blood pressure.
- 198 • Comorbidities (type 2 diabetes mellitus, dialysis chronic kidney disease, non-
199 dialysis chronic kidney disease, coronary heart disease, heart failure, polycystic
200 Ovary syndrome, stroke, overweight, obese, cardiometabolic diseases, peripheral
201 artery disease, heart failure, cardiometabolic risk, cardiac patients, heart disease,
202 transient ischemic attack, metabolic syndrome, intermittent claudication).
- 203 • Population under pharmacological antihypertensive treatment.
- 204 • Age: ≤ 65 years old and > 65 years old.

205 Based on evidence from both experimental and observational studies, reductions of 5 mm Hg
206 on SBP and 2 mm Hg on DBP were deemed as clinically important (26–28).

207 **Managing overlapping systematic reviews**

208 We investigated the degree to which the reviews shared the same included studies (overlap).
209 If we found overlap $\geq 50\%$ included studies between two or more reviews, we reported the
210 results from the most recent reviews with the most detailed description. This assessment was
211 based on the primary studies that provided information on the outcomes of interest (29).

212 **Certainty of the evidence: GRADE approach**

213 We followed the GRADE approach (Grading of Recommendations, Assessment,
214 Development, and Evaluation) to assess the certainty of the evidence supporting the effects
215 of each exercise training modality on blood pressure and adverse events (30). According to
216 the GRADE approach, five factors reduce the certainty of the evidence, these are: 1)
217 limitations in study design; 2) inconsistency in results; 3) indirectness of evidence; 4)
218 imprecision; 5) publication bias. Besides, due to the nature of the intervention and that the
219 outcomes were measured objectively (i.e., sphygmomanometer), we decided not to
220 downgrade the certainty of the evidence for blinding of the participants and personnel of the
221 RCT (performance bias). The certainty of the evidence was rated as high, moderate, low, or
222 very low (30). If available, we used GRADE assessments reported in the included reviews
223 and supplied those with our assessment where the reviews that did not provide any GRADE
224 assessment. We followed the guidance provided by Meader et al. (2014) on assessing
225 GRADE in reviews (31).

226 **RESULTS**

227 **Study selection**


228 We identified 1851 records from database searching. After the removal of 167 duplicates, we
229 screened 1684 titles and abstracts. We excluded 1488 records at this stage and screened 196

230 full texts against our selection criteria. One reviewer (AFL-B) retrieved all full-text
231 publications. We excluded 82 reviews and presented the reasons for their exclusion in
232 (Additional file 2). After the quality appraisal, we excluded 78 reviews of either moderate or
233 low quality (Additional file 3). Eighteen out of the remaining 36 reviews are listed as ongoing
234 (Additional file 4). One review (32) was excluded because of overlap. Finally, we included
235 17 high-quality reviews in the overview. Figure 2 depicts the selection process.

236 **Study characteristics**

237 The 17 reviews included 19,232 adults (ranging from 16 to 84 years old) (33–49). Six (35%)
238 reviews were Cochrane reviews (34,37,41,44,45,47), 29% of the reviews were published in
239 2019 (5 reviews, 29%) (33,39,40,46,48). Australia was the most common country across the
240 included reviews (4 reviews, 23%) (42,45–47), followed by United Kingdom (3 reviews,
241 17%) (34,38,40), Brazil (33,35), and China (36,49) (2 reviews, 12%). Other countries like
242 Canada (48), Germany (43), Netherlands (39), Sweden (37), Chile (44), and Taiwan (41) reported
243 one review each (6%). Type II diabetes was the most common comorbidity (5 reviews, 29%)
244 (38,42,43,47,48), followed by moderate or end-stage renal disease, studied in four reviews
245 (23%) (33,35,37,48). The other four reviews included pre-hypertensive and high blood
246 pressure adults (23%) (36,41,45,46). Other reviews (2 reviews, 12%) included normotensive
247 and healthy adults (41,46), adults with cardiovascular risk factors (i.e., overweight and/or
248 obesity) (2 reviews, 12%) (38,44), and adults with coronary artery disease and heart failure
249 (2 reviews, 12%) (34,49). Other review included adults with acute myocardial infarction (1
250 review, 6 %) (34) and the remaining with intermittent claudication (1 review, 6 %) (39).
251 Three reviews (18%) (37,38,41) reported on participants' physical activity levels or training
252 status; two of those (12%) included sedentary participants (37,38), and the remaining (6%)

253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288



289 **Figure 2.** Preferred reporting items for systematic reviews and meta-analyses (PRISMA)
290 flow-chart of the study selection.

291

292 included physically inactive adults (41). Moreover, the Cochrane collaboration risk of bias
293 tool version 1 was the most used tool to critically appraise the included studies (14 reviews,
294 82%) (33–36,38–44,47–49), and the GRADE approach was the most common grading
295 system (6 reviews, 35%) (34–36,38,40,41). Of note, 11 reviews (65%) did not assess the
296 certainty of the evidence (33,37,39,42–49). Table 1 contains further details on the
297 characteristics of the participants.

298

Review ID, year Country	Number of included trials (participants)	Aim	Intervention and control	Outcomes	Risk of bias and Certainty of evidence
Anderson et al., 2017 (34) United Kingdom (https://doi.org/10.1002/14651858.CD007130) Date search: 2016	10 (2438) Risk factors or comorbidities: Coronary heart disease post-myocardial infarction Revascularization Heart failure	To compare the effect of home-based and supervised center-based cardiac rehabilitation on mortality and morbidity, exercise-capacity, health-related quality of life, and modifiable cardiac risk factors in patients with heart disease.	Int: Aerobic training Con: center-based cardiac rehabilitation Setting: Hospital, University, or community setting	SBP, DBP, adverse events	Cochrane RoB 1 GRADE
B Scapini et al., 2019 (33) Brazil (CRD42015020531) Date search: 2018	14 (573) Risk factors or comorbidities: End-stage renal disease in hemodialysis	To assess the effectiveness of different modalities of exercise training on aerobic capacity, arterial blood pressure and hemodialysis efficiency in adults with end-stage renal disease requiring hemodialysis treatment.	Int 1: Dynamic resistance training Int 2: Aerobic training Int 3: Combined training Con: No intervention, Placebo Setting: Not reported	SBP, DBP	Cochrane RoB 1 Not assessed
Ferrari et al., 2019 (35) Brazil (CRD42017081338 – https://osf.io/fpj54/) Date search: 2019	12 (408) Risk factors or comorbidities: Patients with end-stage renal disease (ESRD)	To Evaluate the impact of different types of intradialytic training on some parameters important for patients with ESRD, through a systematic review and meta-analysis of randomized clinical trials (RCTs) that primarily evaluated outcomes such as Kt/V (Hemodialysis efficiency (dialyzer clearance of urea), aerobic capacity, and blood pressure (BP), as well as other secondary outcomes.	Int 1: Dynamic resistance training Int 2: Aerobic training Int 3: Combined training Con: Standard care, sham exercises (e.g., stretching) Setting: Rehabilitation, home	SBP, DBP, adverse events	Cochrane RoB 1 GRADE
Fu et al., 2020 (36) China	39 (1519) Risk factors or comorbidities:	To assess the comparative effectiveness of different nonpharmacologic interventions for reducing BP in adults with prehypertension to established hypertension and to determine the most efficacious intervention.	Int 1: Dynamic resistance training Int 2: Isometric resistance training Int 3: Aerobic training Int 4: Combined training Con: Standard care, Behavioral change (diet, Reduction in sodium and/or alcohol	SBP, DBP	Cochrane RoB 1 GRADE

	Prehypertensive High blood pressure		intake), Other active interventions (e.g., flexibility, yoga, Qigong), No intervention		
Date search: 2019			Setting: Mixed (e.g., clinic and home)		
Heiwe et al., 2011 (37) Sweden (https://doi.org/10.1002/14651858.CD003236)	11 (419) Risk factors or comorbidities: Moderate kidney failure Kidney transplantation	To assess the effects of regular physical exercise training in adults with CKD and kidney transplant recipients on the following clinically important health outcomes: physical fitness and functioning; cardiovascular dimensions; nutrition; level of physical activity; depression; health-related quality of life; blood lipids; muscle morphology and morphometric systemic inflammation; glucose metabolism; dropout rates; adverse events; and mortality.	Int 1: Dynamic resistance training Int 2: Aerobic training Int 3: Combined training Con: Standard care, Behavioral change (diet, Reduction in sodium and/or alcohol intake), (non-exercise control), usual level of physical activity, usual lifestyle, No exercise training Setting: Home, ambulatory	SBP, DBP, adverse events	Jadad scale Not assessed
Date search: 2010					
Herrod et al., 2018 (38) United Kingdom (CRD42017059443)	50 (3526) Risk factors or comorbidities: Obesity Overweight Type II diabetes	To evaluate the evidence from lifestyle modification RCTs involving participants with a mean age of 65 years or above	Int 1: Dynamic resistance training Int 2: Isometric resistance training Int 3: Aerobic training Int 4: Combined training Con: No intervention Setting: Home	SBP, DBP	Cochrane RoB 1 GRADE
Date search: 2017					
Janssen et al., 2019 (39) Netherlands (CRD42017080706)	7 (333) Risk factors or comorbidities: Intermittent Claudication	To provide a systematic overview of the effectiveness of SET on modifying cardiovascular risk factors in patients with intermittent claudication.	Int: Aerobic training Con: Standard care, Pharmacological interventions, Other active interventions (e.g., flexibility, yoga, Qigong) Setting: Home, hospital, community based	SBP, DBP	Cochrane RoB 1 Not assessed
Date search: 2018					
Kite et al., 2019 (40) United Kingdom (CRD42017062576)	4 (158)	To analyze the evidence on the effectiveness of exercise compared to (i) control or usual care, (ii) diet alone, and (iii) exercise combined with diet, as well as the effectiveness of exercise	Int 1: Aerobic training Int 2: Combined training Con: Standard care, Behavioral change (diet, Reduction in sodium and/or alcohol	SBP, DBP, MAP	Cochrane RoB 1 GRADE


Date search: 2017	Risk factors or comorbidities: Polycystic ovary syndrome (PCOS)	combined with diet compared to (i) control or usual care and (ii) diet alone.	intake), No intervention, Pharmacological interventions Setting: Not reported		
Lee et al., 2021 (41) Taiwan (https://doi.org/10.1002/14651858.CD008823) Date search: 2020	73 (6473) Risk factors or comorbidities: Normotensive High blood pressure	To determine the effect of walking as a physical activity intervention on blood pressure and heart rate.	Int: Aerobic training Con: No intervention Setting: Laboratory, home	SBP, DBP, adverse events	Cochrane RoB 1 GRADE
Ostman et al., 2017 (42) Australia (CRD42017055491) Date search: 2017	16 (364) Risk factors or comorbidities: Type II diabetes Metabolic syndrome	To determine whether high-intensity exercise produced different effect sizes for change in clinical outcomes in MetS compared to vigorous-, moderate- and low-intensity training and sedentary lifestyle. To establish whether the effect on clinical outcomes in MetS varied according to the type of intervention (aerobic versus combined aerobic and resistance training)	Int 1: Aerobic training Int 2: Combined training Con: No intervention Setting: Mixed (e.g., clinic and home)	SBP, DBP	Cochrane RoB 1 Not assessed
Qiu et al., 2014 (43) Germany (CRD42014009515) Date search: 2014	12 (509) Risk factors or comorbidities: Type II diabetes	To examine the association of walking with glycemic control, and other cardiovascular risk factors including weight reduction, blood pressure, and lipoprotein profiles among patients with type 2 diabetes. The second aim was to evaluate whether supervised walking would lead to better improvement in glycemic control versus non-supervised walking among patients with type 2 diabetes.	Int: Aerobic training Con: Standard care, No intervention Setting: Not reported	SBP, DBP, adverse events	Cochrane RoB 1 Not assessed

<p>Seron et al., 2014 (44) Chile (https://doi.org/10.1002/14651858.CD009387)</p> <p>Date search: 2013</p>	<p>3 (794)</p> <p>Risk factors or comorbidities: Cardiovascular risk factors</p>	<p>To assess the effects of exercise training in people with increased cardiovascular risk but without a concurrent cardiovascular disease on general cardiovascular mortality, incidence of cardiovascular events, and total cardiovascular risk.</p>	<p>Int 1: Aerobic training Int 2: Combined training</p> <p>Con: Standard care, Behavioral change (diet, Reduction in sodium and/or alcohol intake), No intervention, Pharmacological interventions</p> <p>Setting: Not reported</p>	<p>SBP, DBP, adverse events</p>	<p>Cochrane RoB 1</p> <p>Not assessed</p>
<p>Shaw et al., 2006 (45) Australia (https://doi.org/10.1002/14651858.CD003817)</p> <p>Date search: 2005</p>	<p>4 (361)</p> <p>Risk factors or comorbidities: Hypertensive Overweight Obese Non-insulin-dependent type II diabetes</p>	<p>To assess the efficacy of exercise as a means of achieving weight loss in people with overweight and obesity.</p>	<p>Int: Aerobic training</p> <p>Con: Behavioral change (diet, Reduction in sodium and/or alcohol intake), No intervention</p> <p>Setting: Clinic, hospital, university campuses, and workplace</p>	<p>SBP, DBP, adverse events</p>	<p>Jadad scale</p> <p>Not assessed</p>
<p>Smart et al., 2019 (46) Australia (CRD42018109167)</p> <p>Date search: 2018</p>	<p>11 (326)</p> <p>Risk factors or comorbidities: Healthy Normotensive Prehypertensive High blood pressure</p>	<p>To examine the efficacy of IRT in managing resting blood pressure. The primary objective was to quantify the change in resting SBP, DBP, and mean arterial pressure (MAP) following more than 3 weeks of IRT. The secondary objective was to explore relationships between baseline characteristics [medication usage, age, sex, BMI, and coronary artery disease (CAD) diagnosis] and the magnitude of changes in resting blood pressure after IRT.</p>	<p>Int: Isometric resistance training</p> <p>Comp: No intervention, Placebo</p> <p>Setting: Home, Office</p>	<p>SBP, DBP, MAP</p>	<p>TESTEX scale</p> <p>Not assessed</p>
<p>Thomas et al., 2006 (47) Australia (https://doi.org/10.1002/14651858.CD002968)</p>	<p>5 (150)</p> <p>Risk factors or comorbidities: Non-insulin-dependent type II diabetes</p>	<p>To assess the effects of exercise in type 2 diabetes mellitus.</p>	<p>Int 1: Aerobic training Int 2: Combined training Int 3: Dynamic resistance training</p> <p>Con: No intervention</p>	<p>SBP, DBP, adverse events</p>	<p>Cochrane RoB 1</p> <p>Not assessed</p>

Date search: 2005			Setting: Community		
Thompson et al., 2019 (48) Canada (No reported)	12 (335) Risk factors or comorbidities: Chronic kidney disease Cardiovascular disease Type II diabetes	To evaluate the evidence for exercise as a strategy to lower blood pressure in people with non-dialysis dependent CKD	Int: Aerobic training Con: No intervention Setting: Mixed (center and at home)	SBP, DBP, MAP	Cochrane RoB 1 Not assessed
Date search: 2017					
Xie et al., 2017 (49) China (Not reported)	8 (376) Risk factors or comorbidities: Chronic heart failure Coronary artery disease	To compare the effects of high-intensity interval training (INTERVAL) and moderate-intensity continuous training (CONTINUOUS) on aerobic capacity in cardiac patients.	Int: Aerobic training – HIIT Con: Aerobic training - MICT Setting: Not reported	SBP, DBP	Cochrane RoB 1 Not assessed
Date search: 2016					
BMI: Body mass index; CKD: chronic kidney disease; CFR: cardiorespiratory fitness; Comp: comparator; DBP: diastolic blood pressure; ERSD: end-stage renal disease in hemodialysis; GRADE: grading of recommendations, assessment, development, and evaluation; Int: interventions; IRT: isometric resistance training; MBP: mean blood pressure; Mets: metabolic syndrome; RCTs: randomized controlled trials; RoB: risk of Bias; SBP: systolic blood pressure; SET: supervised exercise therapy					

301 **Overlap among RCTs included in the reviews**

302 The included reviews were published between 2006 to 2021 and included 290 RCTs that
303 reported on our outcomes of interest. Among those, 40 RCTs (14%) overlapped across
304 reviews, whereas 250 RCTs (86%) were ‘unique’ and more recently published (Additional
305 file 5). 197 RCTs (68%) reported the country where they were conducted. All in all, 23% of
306 the RCTs were from North America, 21% from Europe, 11% from Asia, 4% from Oceania,
307 and 3% from South America. See Figure 3.



309 **Figure 3.** Geographic overview of the randomized controlled trials in the included
310 systematic reviews.

311

312

313 **Description of the interventions**

314 The most common exercise training modality investigated for the reviews included was AET
315 (16 reviews , 94%) (33–45,47–49), followed by CT (9 reviews, 53%) (33,35–
316 38,40,42,44,47), DRT (6 reviews, 35%) (33,35–38,47), and IRT (3 reviews, 18) (36,38,46).
317 Twelve reviews (71%) reported the setting in which the intervention took place (34–
318 39,41,42,45–48). Besides, most of the interventions were partially supervised (10 reviews,
319 58%) (33–35,37,38,40,43,46–48). See Additional file 6.

320 **Aerobic training (16 reviews)**

321 Overall, AET programs had a frequency of 3 to 5 days per week, implemented from 4 to 64
322 weeks, and each session lasted between 10 to 60 minutes. The volume per week ranged from
323 90 to 180 minutes, whereas the most common training intensity was 60% to 85% of the
324 maximum heart rate. HIIT interventions were carried out at 80% to 95% of the VO₂ peak.

325 **Dynamic resistance training (6 reviews)**

326 The most common prescription of the DRT programs comprised a frequency of 2, 3, and 4
327 days per week. The DRT programs were run from 3 to 48 weeks, (8 weeks was the most
328 reported length), and each session lasted around 20-30 minutes. The most common volume
329 was 1 to 3 sets per 6 to 30 repetitions with 6 to 13 exercises per session.

330 **Isometric resistance training (3 reviews)**

331 The most common prescription of the IRT programs comprised a frequency of 3 days per
332 week. The IRT programs were implemented from 4 to 12 weeks, each session had a duration
333 of 12 to 16 minutes. The most common volume was 4 sets per 2 minutes, with 1 to 3 minutes
334 rest between sets. The most common exercises used were manual dynamometry and leg
335 extensions isokinetic dynamometry.

336 **Combined training (9 reviews)**

337 In general, the reviews that evaluated CT reported similar parameters of FITT -VP to those
338 described above for AET and DRT.

339 **Quality appraisal**

340 Overall, few systemic reviews had specific methodological limitations that could introduce
341 bias. The quality appraisal of the included and excluded reviews is presented in Additional
342 file 3. Two reviews (12%) did not report the review protocol (48,49); one review (6%) failed
343 to use applicable for methods to combine the findings of studies (44). Five reviews (30%)
344 did not run comprehensive searches in grey literature resources (33,43,44,48,49). Some
345 reviews (23%) provided no list of excluded studies (36,38,39,43). Additional file 3 presents
346 further details about the quality appraisal.

347 **Results of syntheses**

348 In order to facilitate the use of this review in evidence-informed decision making, we report
349 in the main body of the manuscript the results of the comparisons that are most often studied
350 by international guidelines (16,50) alongside the longest follow-up (i.e., short to long term:
351 4 to 64 weeks) as recommended by the Cochrane handbook (15):

- 352 • Comparison 1: any AET vs control
- 353 • Comparison 2: walking AET vs control
- 354 • Comparison 3: high-intensity interval training vs moderate-intensity continuous
355 training
- 356 • Comparison 4: home-based vs supervised center-based cardiac rehabilitation
- 357 • Comparison 5: combined training vs control
- 358 • Comparison 6: exercise training (ET) vs control

- 359 • Comparison 7: isometric resistance training vs control
- 360 • Comparison 8: dynamic resistance training vs control


361 Additional file 7 presents the results for the remaining comparisons and their follow-up
362 periods (i.e., any AET vs control; walking vs control; AET vs yoga; AET vs salt restriction;
363 AET vs Tai Chi; aerobic training vs aerobic training plus Dietary Approaches to Stop
364 Hypertension (DASH); high-intensity interval training vs moderate-intensity aerobic
365 training; home-based vs supervised center-based cardiac rehabilitation; combined training vs
366 control; exercise training vs control; exercise training vs no intervention; exercise training vs
367 diet; exercise training vs diet plus exercise training; isometric resistance training vs control;
368 dynamic resistance training vs control; dynamic resistance training vs aerobic training;
369 dynamic resistance training vs yoga). See Figure 4.

370 In light of the richness of information reported across reviews, we present effect data and the
371 corresponding assessment of the certainty of the evidence for the following follow-up periods
372 (Tables 2-6 and Additional file 7):

- 373 • Short term (up to 16 weeks)
- 374 • Short to middle term (12 to 28 weeks)
- 375 • Short to long term (4 to 64 weeks)
- 376 • Middle term (up to 24-28 weeks)
- 377 • Middle to long term (24 to 64 weeks)
- 378 • Long term (48 to 64 weeks)

379 Seventeen (100%) reviews reported on SBP and DBP (33–49); three reviews reported on
380 MBP (18%) (40,46,48). Eight reviews (48%) reported on adverse events related to the

381 exercise training interventions (34,35,37,41,43–45,47); we used a narrative synthesis
382 approach for this outcome due to the incomplete information reported by the reviews.
383 Additional file 8 presents our assessment of the certainty of the evidence for all comparisons
384 and Additional file 9 provides further details about effect estimates.



387 **Primary outcomes: SBP, DBP, and MBP**

388 **Aerobic training**

389 Four comparisons reported effect data for AET (i.e., any AET vs control; walking aerobic
390 training vs control; HIIT versus MICT; Home-based versus supervised centre-based cardiac
391 rehabilitation). Results for these comparisons are summarized in Table 2.

392 **Comparison 1:** Any aerobic training versus control.

393 Seven reviews assessed the effects of any aerobic training on SBP and DBP compared with
394 control groups in adults at short to long-term follow-up (33,35–38,42). One review assessed
395 the effects of this intervention on MBP at short-term follow-up (40). The reviews included
396 participants with different diagnoses and risk factors, such as high blood pressure (38),
397 kidney failure (37), type II diabetes, and metabolic syndrome (42). Participants' age ranged
398 from 21 to 71 years (33,35–38,40,42). See Table 1.

399 **Systolic blood pressure: short to long term follow-up**

400 Seven reviews reported data for this follow-up period. In order to provide a more precise
401 analysis of the certainty of the evidence, we decided to report two reviews in a separate
402 analysis (36,38) since these reviews had important methodological strengths (e.g., narrow
403 confidence intervals and large sample sizes). This approach was followed in the analysis of
404 SBP and DBP, as follows:

405 Herrod et al., 2018 reported evidence of a clinically relevant difference in SBP between any
406 AET and control in normotensive or high blood pressure adults (24 RCTs; N=1709; MD -
407 5.09 mm Hg, 95% CI -7.22 to -2.97) at 12 to 48 weeks follow-up (38). Similar findings were
408 reported by Fu et al., 2020 on SBP in prehypertensive adults (27 RCTs; N=1029; MD -6.60
409 mm Hg, 95% CI -8.23 to -4.98) for this follow-up (36). These findings were further

410 confirmed by the same review (36) in the subgroup of adults with high blood pressure (24
411 RCTs; N=896; MD -6.11 mm Hg, 95% CI -7.82 to -4.45). Moderate quality evidence
412 indicates that any AET probably reduces SBP compared to control in adults with either
413 normotensive, prehypertensive, or with high blood pressure values at short to long-term
414 follow-up (Table 2).

415 Data from Ostman et al. 2017 (42) suggest that any AET compared to control leads to little
416 effect on SBP in adults with type II diabetes or metabolic syndrome at short to long term
417 follow-up (15 RCTs; N=364; MD -2.54 mm Hg, 95% CI -4.34 to -0.75). Similar evidence
418 was reported by a review on SBP in adults with end-stage renal disease at 8 to 40 weeks
419 follow-up (10 RCTs; N=332; MD -10.07 mm Hg, 95% CI -16.35 to -3.78) (35). No
420 differences between any AET and control were observed for SBP in adults with end-stage
421 renal disease undergoing hemodialysis at 12 to 40 weeks follow-up (8 RCTs; N=204; MD -
422 2.84 mm Hg, 95% CI -11.33 to 5.65) (33). Besides, Heiwe et al. 2011 (37), reported narrative
423 data of no difference between any AET and control on SBP in adults with either moderate
424 kidney failure, dialysis treatment, or kidney transplantation (37).

425 **Diastolic blood pressure: short to long term follow-up**

426 Herrod et al., 2018 found that any AET led to clinically important reductions in DBP
427 compared with control (24 RCTs; N=1709; MD -2.20 mm Hg, 95% CI -3.08 to -1.31) at
428 short to long term follow-up in normotensive or high blood pressure adults (38). These
429 findings were further confirmed by Fu et al., 2020 in the subgroup of prehypertensive (27
430 RCTs; N=1029; -4.44 mm Hg, 95% CI -5.57 to -3.31) and high blood pressure adults (22
431 RCTs; N=848; WMD -4.01 mm Hg, 95% CI -5.30 to -2.74), for this follow-up (36).
432 Moderate quality evidence indicates that any AET probably reduces DBP compared to

433 control in adults who either are normotensive or prehypertensive or have high blood pressure
434 at 6 to 64 weeks follow-up (Table 2). Data from Ostman et al., 2017 reported evidence of a
435 clinically relevant reduction in DBP between any AET and control in adults with type II
436 diabetes or metabolic syndrome at short to long-term follow-up (14 RCTs; N=337; MD -2.27
437 mm Hg, 95% CI -3.47 to -1.06) (42). Besides, no differences between any AET and control
438 in DBP were found in adults with end-stage renal disease for this follow-up (10 RCTs;
439 N=334; MD -2.96 mm Hg, 95% CI -7.71 to 1.78) (35).

440 These findings were further confirmed by Scapini et al., 2019 on DBP in adults with end-
441 stage renal disease undergoing hemodialysis at 12 to 40 weeks follow-up (8 RCTs; N=204;
442 MD 0.68 mm Hg, 95% CI -4.01 to 5.37) (33). Similarly, Heiwe et al., 2011 observed no
443 difference between groups on DBP in adults with either moderate kidney failure, dialysis
444 treatment, or kidney transplantation at short to long term follow-up (6 RCTs; N=202; MD -
445 0.11 mm Hg, 95% CI -2.88 to 2.66) (37). It is uncertain whether any AET reduces DBP
446 compared to control in adults with either type II diabetes, metabolic syndrome, renal diseases,
447 end-stage renal disease, or kidney transplantation at short to long-term follow-up because the
448 quality of evidence is very low (Table 2).

449 **Mean blood pressure: short term follow-up**

450 Findings from of Kite et al., 2019 (40) provided very low-quality evidence on the effects of
451 any AET compared to control on MBP values in adults with polycystic ovary syndrome up
452 to 16 weeks follow-up (1 RCTs; N=14; MD -6.8 mm Hg, 95% CI -10.6 to -3.0) (Table 2).

453 **Comparison 2: Walking aerobic training versus control.**

454 Two reviews studied the effects of walking aerobic training on SBP and DBP compared with
455 control groups in adults at short to long-term follow-up (41,43). These reviews included

456 adults with different diagnoses and risk factors, such as normotensive and high blood
457 pressure adults (41), and type II diabetes (43). Participants' age ranged from 16 to 84 years
458 (41,43).

459 **Systolic blood pressure: short to long term follow-up**

460 Lee et al., 2021, found that walking AET reduced SBP relative to control in normotensive or
461 high blood pressure adults at short to long-term follow-up (73 RCTs; N=5060; MD -4.11 mm
462 Hg, 95% CI -5.22 to -3.01) (41). In contrast, Qiu et al., 2014 found no evidence of such
463 difference between groups in adults with type II diabetes at 8 to 6 weeks follow-up (11 RCTs;
464 N=497; MD -1.69 mm Hg, 95% CI -5.22 to 1.85) (43). Compared to control, low certainty
465 of evidence suggests that walking AET may reduce SBP in adults who either are
466 normotensive, have high blood pressure, or have type II diabetes at short to long-term follow-
467 up (Table 2).

468 **Diastolic blood pressure: short to long term follow-up**

469 Lee et al., 2021 reported evidence of a difference in DBP between walking AET and control
470 (69 RCTs; N=4711; MD -1.79 mm Hg, 95% CI -2.51 to -1.07) in adults who either are
471 normotensive or have high blood pressure at short to long-term follow-up (41). These
472 findings were further confirmed by Qiu et al., 2014 on DBP in adults with type II diabetes
473 (11 RCTs; N=497; MD -1.97 mm Hg, 95% CI -3.94 to -0.0) (43). Compared to control, low
474 certainty of evidence suggests that walking AET may reduce DBP in adults who either are
475 normotensive, have high blood pressure, or have type II diabetes at short to long-term follow-
476 up (Table 2).

477 **Comparison 3:** High-intensity interval training (HIIT) versus moderate-intensity continuous
478 training (MICT).

479 One review assessed the effects of HIIT compared with MICT on SBP and DBP at short-
480 term follow-up (49) in adults with different diagnoses, such as chronic heart failure or
481 coronary artery disease (participants' mean age 61 years) (49).

482 **Systolic and diastolic blood pressures: short term follow-up**

483 Xie et al., 2017 found lack of evidence of an effect between groups on SBP in adults with
484 chronic heart failure or coronary artery disease at 4 to 12 weeks follow-up (8 RCTs; N=376;
485 MD -0.09 mm Hg, 95% CI -4.82 to 4.65) (49). Similar findings were reported for DBP (8
486 RCTs; N=376; MD -0.79 mm Hg, 95% CI -3.75 to 2.16) (49). It is uncertain whether HIIT
487 or MICT may reduce SBP and DBP in adults with chronic heart failure or coronary artery
488 disease at short-term follow-up because the quality of evidence is very low (Table 2).

489 **Comparison 4:** Home-based versus supervised centre-based cardiac rehabilitation.

490 One review assessed the effects of home-based cardiac rehabilitation on SBP and DBP
491 compared with supervised centre-based cardiac rehabilitation at short to long-term follow-up
492 (34) in adults with either coronary heart disease, post-myocardial infarction,
493 revascularization, or heart failure. Participants' age ranged 52 to 69 years (34).

494 **Systolic and diastolic blood pressures: short term follow-up**

495 Anderson et al., 2017 (34) found evidence of no difference between home-based cardiac
496 rehabilitation and supervised centre-based cardiac rehabilitation on SBP in adults with either
497 coronary heart disease, post-myocardial infarction, revascularization, or heart failure at 4 to
498 12 weeks follow-up (10 RCTs; N=1292; MD -0.27 mm Hg, 95% CI -3.13 to 2.60). Similar
499 findings were reported for DBP (9 RCTs; N=1146; MD 0.74 mm Hg, 95% CI -1.04 to 2.53).

500 Compared to supervised centre-based cardiac rehabilitation, low quality evidence indicates
501 that home-based cardiac rehabilitation may not reduce neither SBP nor DBP in this
502 population at short-term follow-up (Table 2).

Table 2. Summary of findings for the comparison: Aerobic training vs control for systolic, diastolic, and mean blood pressure

Aerobic training vs Control						
Intervention: aerobic training						
Comparison: control						
Setting: mixed (Center, home, hospital, community-based, rehabilitation, laboratory, clinic, University)						
Outcomes	Population	Relative effect (95% CI)	Anticipated absolute effect* (95% CI)		N° of Participants (studies)	Certainty of the evidence (GRADE)
			Assumed risk with control	Assumed risk with intervention		
			Systolic blood pressure – short to long term follow-up (6 to 64 weeks)			
Systolic blood pressure (short to long term 12-48 weeks)**	Normotensive High blood pressure	MD -5.09 (-7.22 to -2.97)	Not estimable	Mean SBP (mm Hg) was 5.09 lower (7.22 lower to 2.97 lower)	1709 (24) ^a	⊕⊕⊕⊖ Moderate ^{1,2,3}
Systolic blood pressure (short to long term 6-64 weeks)**	Prehypertensive	WMD -6.60 (-4.98 to -8.23)	Not estimable	Mean SBP (mm Hg) was 6.60 lower (4.98 lower to 8.23 lower)	1029 (27) ^b	
Systolic blood pressure (short to long term 6-64 weeks)**	High blood pressure	WMD -6.11 (-4.45 to -7.82)	Not estimable	Mean SBP (mm Hg) was 6.11 lower (4.45 lower to 7.82 lower)	896 (24) ^b	
			Systolic blood pressure – short to long term follow-up (4 to 52 weeks)			
Systolic blood pressure (short to long term 8-52 weeks)**	Type II diabetes metabolic syndrome	MD -2.54 (-4.34 to -0.75)	Not estimable	Mean SBP (mm Hg) was 2.54 lower (4.34 lower to 0.75 lower)	364 (15) ^c	⊕⊕⊕⊖ Low ^{1,2,4}
Systolic blood pressure (short to long term 8-40 weeks)**	End-stage renal disease	MD -10.07 (-16.35 to -3.78)	The mean SBP (mm Hg) range was from 132.2 to 179	Mean SBP (mm Hg) was 10.07 lower (16.35 lower to 3.78 lower)	332 (10) ^d	
Systolic blood pressure (Short to long term 12-40 weeks)**	End-stage renal disease on hemodialysis	MD -2.84 (-11.33 to 5.65)	The mean SBP (mm Hg) range was from 131 to 179	Mean SBP (mm Hg) was 2.84 lower (11.33 lower to 5.65 higher)	204 (8) ^e	
Systolic blood pressure (short to long term 4-52 weeks)**	Moderate kidney failure Dialysis treatment Kidney transplantation	Not estimable	-	-	202 (6) ^f	
			Systolic blood pressure – short to long term follow-up (4 to 64 weeks)			

Systolic blood pressure (short to long term 4 to 64 weeks)***	Normotensive High blood pressure	MD -4.11 (-5.22 to -3.01)	The MD SBP (mm Hg) range was from -8.4 to 7.27	Mean SBP (mm Hg) was 4.11 lower (5.22 lower to 3.01 lower)	5060 (73) ^g	⊕⊕⊕⊕ Low ^{2,7}
Systolic blood pressure (short to long term 8-36 weeks)***	Type II diabetes	MD -1.69 (-5.22 to 1.85)	Not estimable	Mean SBP (mm Hg) was 1.69 lower (5.22 lower to 1.85 higher)	497 (11) ^h	
Systolic blood pressure – short term follow-up (4 to 12 weeks)						
Systolic blood pressure (short term 4 to 12 weeks)****	Chronic heart failure Coronary artery disease	MD -0.09 (-4.82 to 4.65)	The mean SBP (mm Hg) range was from -1 to -12	Mean SBP (mm Hg) was 0.09 lower (4.82 lower to 4.65 higher)	376 (8) ⁱ	⊕⊕⊕⊕ Very Low ^{2,8,9}
Systolic blood pressure – short to long term follow-up (12 to 48 weeks)						
Systolic blood pressure (short to long term 12 to 48 weeks)*****	Coronary heart disease Post-myocardial infarction Revascularization Heart failure	MD -0.27 (-3.13 to 2.60)	The MD SBP (mm Hg) range was from -4.3 to 138	Mean SBP (mm Hg) was 0.27 lower (3.13 lower to 2.60 higher)	1292 (10) ^j	⊕⊕⊕⊕ Low ^{2,8}
Diastolic blood pressure – short to long term follow-up (6 to 64 weeks)						
Diastolic blood pressure (short to long term 12-48 weeks)**	Normotensive High blood pressure	MD -2.20 (-3.08 to -1.31)	Not estimable	Mean DBP (mm Hg) was 2.20 lower (3.08 lower to 1.31 lower)	1709 (24) ^a	⊕⊕⊕⊕ Moderate ^{1,2,3}
Diastolic blood pressure (short to long term 6-64 weeks)**	Prehypertensive	WMD -4.44 (-5.57 to -3.31)	Not reported*	Mean DBP (mm Hg) was 4.44 lower (5.57 lower to 3.31 lower)	1029 (27) ^b	
Diastolic blood pressure (short to long term 6-64 weeks)**	High blood pressure	WMD -4.01 (-5.30 to -2.74)	Not reported*	Mean DBP (mm Hg) was 4.01 lower (5.30 lower to 2.74 lower)	848 (22) ^b	
Diastolic blood pressure – short to long term follow-up (4 to 52 weeks)						
Diastolic blood pressure (short to long term 8-52weeks)**	Type II diabetes metabolic syndrome	MD -2.27 (-3.47 to -1.06)	Not reported*	Mean DBP (mm Hg) was 2.27 lower (3.47 lower to 1.06 lower)	337 (14) ^c	⊕⊕⊕⊕ Very Low ^{1,2}
Diastolic blood pressure (short to long term 8-40 weeks)**	End-stage renal disease	MD -2.96 (-7.71 to 1.78)	The mean DBP (mm Hg)	Mean DBP (mm Hg) was 2.96 lower (7.71 lower to 1.78 higher)	334 (10) ^d	

			range was from 0.5 to 90.42			
Diastolic blood pressure (Short to long term 12-40 weeks)**	End-stage renal disease on hemodialysis	MD 0.68 (-4.01 to 5.37)	The mean DBP (mm Hg) range was from 131 to 179	Mean DBP (mm Hg) was 0.68 higher (4.01 lower to 5.37 higher)	204 (8) ^e	
Diastolic blood pressure (short to long term 4-48 weeks)**	Moderate kidney failure Dialysis treatment Kidney transplantation	MD -0.11 (-2.88 to 2.66)	The mean DBP (mm Hg) range was from 72.8 to 90.6	Mean DBP (mm Hg) was 0.11 lower (2.88 lower to 2.66 higher)	202 (6) ^f	
			Diastolic blood pressure – short to long term follow-up (4 to 64 weeks)			
Diastolic blood pressure (short long term 4 to 64 weeks)***	Normotensive High blood pressure	MD -1.79 (-2.51 to -1.07)	The MD DBP (mm Hg) range was from -5 to 4.82	Mean DBP (mm Hg) was 1.79 lower (2.51 lower to 1.07 lower)	4711 (69) ^g	⊕⊕⊕⊕ Low ^{2,7}
Diastolic blood pressure (short to long term 8-36 weeks)***	Type II diabetes	MD -1.97 (-3.94 to -0.0)	Not estimable	Mean DBP (mm Hg) was 1.97 lower (3.94 lower to 0.0 lower)	497 (11) ^h	
			Diastolic blood pressure – short term follow-up (4 to 12 weeks)			
Diastolic blood pressure (short term 4 to 12 weeks)****	Chronic heart failure Coronary artery Disease	MD -0.79 (-3.75 to 2.16)	The mean DBP (mm Hg) range was from 0 to -5	Mean DBP (mm Hg) was 0.79 lower (3.75 lower to 2.16 higher)	376 (8) ⁱ	⊕⊕⊕⊕ Very Low ^{2,8,9}
			Diastolic blood pressure – short to long term follow-up (12 to 48 weeks)			
Diastolic blood pressure (short to long term 12 to 48 weeks)*****	Coronary heart disease Post-myocardial infarction Revascularization Heart failure	MD 0.74 (-1.04 to 2.53)	The MD DBP (mm Hg) range was from -3.3 to 87	Mean DBP (mm Hg) was 0.74 higher (1.04 lower to 2.53 higher)	1146 (9) ^j	⊕⊕⊕⊕ Low ^{2,8}
			Mean blood pressure – short term follow-up (up to 16 weeks)			
Mean blood pressure (short term up to 16 weeks)**	Polycystic ovary syndrome	MD -6.8 (-10.6 to -3.0)	Not estimable	Mean MBP (mm Hg) was 6.8 lower (10.6 lower to 3.0 lower)	14 (1) ^k	⊕⊕⊕⊕ Very Low ^{5,6}

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). AET: aerobic training; CI: Confidence interval; DBP: diastolic blood pressure; MD: mean difference; RCT: randomized controlled trial; SBP: systolic blood pressure; WMD: weighted mean difference.

** Any aerobic training versus control

*** Walking aerobic training versus control

**** High-intensity interval training (HIIT) versus Moderate-intensity aerobic training (MICT)

***** Home-based cardiac rehabilitation versus supervised centre-based cardiac rehabilitation

^aHerrod et al., 2018; ^bFu et al., 2020; ^cOstman et al., 2017; ^dFerrari et al., 2019; ^eScapini et al., 2019; ^fHeiwe et al., 2011, ^kKite et al., 2019; ^gQiu et al., 2014; ^hLee et al., 2021; ⁱXie et al., 2019; ^jAnderson et al., 2017.

¹ Downgraded by two levels due to selection bias (random sequence generations and allocation concealment), detection bias (unblinded outcome assessor), incomplete outcome data (attrition bias), and selective reporting (reporting bias).

² Downgraded by one level due to inconsistency (there was statistically significant heterogeneity).

³ Upgraded by two levels due to very large effect (the effect is rapid and consistent across subjects, no serious problems with precision due to narrow confidence intervals and large sample size).

⁴ Upgraded by one level due to very large effect (the effect is rapid and consistent across subjects, no serious problems due to narrow confidence)

⁵ Downgraded by two levels due to selection bias (random sequence generations and allocation concealment), detection bias (unblinded outcome assessor), selective reporting (reporting bias), and other bias (contamination).

⁶ Downgraded by one level due to small sample size (imprecision).

⁷ Downgraded by one level due to selection bias (random sequence generations and allocation concealment), detection bias (unblinded outcome assessor), and incomplete outcome data (attrition bias)

⁸ Downgraded by one level due to detection bias (unblinded outcome assessor).

⁹ Downgraded by one level due to wide confidence intervals (imprecision).

505 **Comparison 5: Combined training versus Control**

506 Four reviews assessed the effects of combined training compared with control on SBP and
507 DBP in adults at short to long-term follow-up (33,37,38,42). The reviews included
508 participants with different diagnoses and risk factors, such as normotensive adults and high
509 blood pressure (38), kidney failure (37), metabolic syndrome (42), or end-stage renal disease
510 (33). Participants' mean age was 71 years (33,37,38,42). See Table 1.

511 **Systolic blood pressure: short to long term follow-up**

512 Heiwe et al., 2011, reported evidence of a clinically relevant difference in SBP between any
513 AET and control in adults with kidney failure at short to long-term follow-up (4 RCTs;
514 N=186; MD -5.80 mm Hg, 95% CI -10.41 to -1.19) (37). Similar findings were reported by
515 Herrod et al., 2018 on SBP in normotensive or high blood pressure adults for this follow-up
516 (12 RCTs; N=1237; MD -5.86 mm Hg, 95%CI -8.27 to -3.45) (38). These findings were
517 further confirmed by Scapini et al., 2019 in adults with end-stage renal disease at 12 to 40
518 weeks (7 RCTs; N=292; MD -8.53 mm Hg, 95% CI -13.29 to -3.76) (33), and by Ostman et
519 al., 2017 in metabolic syndrome adults at short to long-term follow-up (3 RCTs; N=652; MD
520 -3.79 mm Hg, 95% CI -6.18 to -1.40) (42). Low certainty of evidence suggests that CT may
521 reduce SBP compared to control in adults who either are normotensive, have high blood
522 pressure, kidney failure, metabolic syndrome, or end-stage renal disease at short to long-term
523 follow-up (Table 3).

524 **Diastolic blood pressure: short to long term follow-up**

525 Heiwe et al., 2011, found that CT led to clinically important differences in DBP compared to
526 control in adults with kidney failure at short to long-term follow-up (4 RCTs; N=229; MD -
527 3.77 mm Hg, 95% CI -5.94 to -1.61) (37). Similar findings were reported by Herrod et al.,

528 2018 in normotensive or high blood pressure adults for this follow-up (12 RCTs; N=1237;
529 MD -3.51 mm Hg, 95%CI -4.43 to -2.59) (38), by Scapini et al., 2019 in adults with end-
530 stage renal disease at 12 to 40 weeks (7 RCTs; N=292; MD -4.57 mm Hg, 95% CI -6.24 to -
531 2.90) (33), and finally by Ostman et al., 2017 in metabolic syndrome adults at short to long-
532 term follow-up (3 RCTs; N=652; MD -0.23 mm Hg, 95% CI -3.53 to -1.55) (42). Moderate
533 quality evidence indicates that CT probably reduces DBP compared to control in adults who
534 either are normotensive, have high blood pressure, kidney failure, metabolic syndrome, or
535 end-stage renal disease at 4 to 52 weeks follow-up (Table 3).

Combined training vs Control						
Intervention: combined training						
Comparison: control						
Setting: mixed (Center, home, hospital, community-based, rehabilitation)						
Outcomes	Population	Relative effect (95% CI)	Anticipated absolute effect* (95% CI)		N° of participants (studies)	Certainty of the evidence (GRADE)
			Assumed risk with control	Assumed risk with intervention		
			Systolic blood pressure – short to long term follow-up (4 to 52 weeks)			
Systolic blood pressure (short to long term 12-48 weeks)	Normotensive High blood pressure	MD -5.86 (-8.27 to -3.45)	Not estimable	Mean SBP (mm Hg) was 5.86 lower (8.27 lower to 3.45 lower)	1237 (12) ^a	⊕⊕⊕⊖ Low ^{1,2}
Systolic blood pressure (short to long term 8-52 weeks)	Metabolic syndrome	MD -3.79 (-6.18 to -1.40)	Not estimable	Mean SBP (mm Hg) was 3.79 lower (6.18 lower to 1.40 lower)	652 (3) ^b	
Systolic blood pressure (short to long term 12 to 40 weeks)	End-stage renal disease and on hemodialysis	MD -8.53 (-13.29 to -3.76)	The mean SBP (mm Hg) range was from 133.7 to 153.1	Mean SBP (mm Hg) was 8.53 lower (13.29 lower to 3.76 lower)	292 (7) ^c	
Systolic blood pressure (short to long term 4-48 weeks)	Moderate kidney failure Dialysis treatment Kidney transplantation	MD -5.80 (-10.41 to -1.19)	The mean SBP (mm Hg) range was from 139.3 to 153.1	Mean SBP (mm Hg) was 5.80 lower (10.4 lower to 1.19 lower)	186 (4) ^d	
			Diastolic blood pressure – short to long term follow-up (4 to 52 weeks)			
Diastolic blood pressure (short to long term 12-48 weeks)	Normotensive High blood pressure	MD -3.51 (-4.43 to -2.59)	Not estimable	Mean DBP (mm Hg) was 3.57 lower (4.43 lower to 2.59 lower)	1237 (12) ^a	⊕⊕⊕⊖ Moderate ²
Diastolic blood pressure (short to long term 8-52 week)	Metabolic syndrome	MD -0.23 (-3.53 to 1.55)	Not estimable	Mean DBP (mm Hg) was 0.23 lower (3.53 lower to 1.55 higher)	652 (3) ^b	
Diastolic blood pressure (short to long term 12 to 40 weeks)	End-stage renal disease and on hemodialysis	MD -4.57 (-6.24 to -2.90)	The mean DBP (mm Hg) range was from 78.4 to 86.0	Mean DBP (mm Hg) was 4.57 lower (13.29 lower to 3.76 lower)	292 (7) ^c	
Diastolic blood pressure (short to long term 4-48 weeks)	Moderate kidney failure Dialysis treatment Kidney transplantation	MD -3.77 (-5.94 to -1.61)	The mean DBP (mm Hg) range was from 76.9 to 81.7	Mean DBP (mm Hg) was 3.77 lower (5.94 lower to 1.61 lower)	229 (4) ^d	

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). CI: Confidence interval; CT: combined training; DBP: diastolic blood pressure; MD: mean difference; RCT: randomized controlled trial; SBP: systolic blood pressure.

^aHerrod et al., 2018; ^bOstman et al., 2017; ^cScapini et al., 2019; ^dHeiwe et al., 2011.

¹ Downgraded by one level due to selection bias (random sequence generations and allocation concealment), detection bias (unblinded outcome assessor), and incomplete outcome data (attrition bias).

² Downgraded by one level due to inconsistency (there was statistically significant heterogeneity)

537

538

539 **Comparison 6: Exercise training versus Control**

540 Three reviews reported on the effects of exercise training in SBP and DBP compared with
541 control groups at short to long-term follow-up (37,47,48). One review studied the effects of
542 this intervention in MBP at short-term follow-up (48). The reviews included adults with
543 different diagnoses and risk factors, such as moderate kidney failure, kidney transplantation
544 (37), chronic kidney disease, cardiovascular disease, type II diabetes (48), or type II diabetes
545 and non-insulin-dependent adults (47). Participants' age ranged from 52 to 71 years
546 (37,47,48).

547 **Systolic blood pressure: short to long term follow-up**

548 Heiwe et al., 2011 observed evidence of no effect between ET and control on SBP in
549 moderate kidney failure or kidney transplantation adults at short to long-term follow-up (8
550 RCTs; N=347; MD -5.88 mm Hg, 95% CI -9.48 to 2.28; very low quality of evidence) (37).
551 Similar findings were reported by the same review in SBP when the ET was performed at
552 low intensity (< 60%) (3 RCTs; N=147; MD -0.86 mm Hg, 95% CI -7.82 to 6.10; very low
553 quality of evidence). Different findings were reported by Heiwe et al., 2011 (37), who found
554 that high-intensity ET ($\geq 60\%$) may reduce SBP compared to control in adults with either
555 moderate kidney failure or kidney transplantation at this follow-up (5 RCTs; N=211; MD -
556 4.60 mm Hg, 95% CI -8.83 to -0.37; low quality of evidence).

557 Thompson et al., 2019 reported evidence of no difference between ET and control on SBP in
558 adults with either chronic kidney disease, cardiovascular disease, or type II diabetes at short
559 to long-term follow-up (10 RCTs; N=335; MD -4.33 mm Hg, 95% CI -9.04 to 0.38) (48).
560 Similar findings were reported by Thomas et al., 2006 in type II diabetes, non-insulin-
561 dependent adults at 8 to 48 weeks follow-up (4 RCTs; N=127; MD -4.16 mm Hg, 95% CI -

562 9.46 to -1.14) (47). Overall, low certainty of evidence suggests that ET may reduce SBP
563 compared to control in adults who either have moderate kidney failure, kidney
564 transplantation, chronic kidney disease, cardiovascular disease, or type II diabetes at short to
565 long-term follow-up (Table 4).

566 **Diastolic blood pressure: short to long term follow-up**

567 Heiwe et al., 2011 reported evidence of a clinically important difference in DBP between ET
568 and control in adults who either have moderate kidney failure or underwent kidney
569 transplantation at short to long-term follow-up (10 RCTs; N=419; MD -2.32 mm Hg, 95%
570 CI -4.05 to -0.59). Similar findings were reported by the same review in DBP when the ET
571 was performed with high intensity ($\geq 60\%$) at 8 to 48 weeks follow-up (6 RCTs; N=254; MD
572 -3.98 mm Hg, 95% CI -6.05 to -1.90; low quality of evidence) (37). Furthermore, Thompson
573 et al., 2019 found evidence of no difference between ET and control on DBP in adults with
574 either chronic kidney disease, cardiovascular disease, or type II diabetes for this follow-up
575 (8 RCTs; N=303; MD -1.18 mm Hg, 95% CI -4.76 to 2.40) (48). These findings were further
576 confirmed by Thomas et al., 2006 on DBP in type II diabetes non-insulin-dependent adults
577 at 8 to 48 weeks follow-up (3 RCTs; N=78; MD -0.13 mm Hg, 95% CI -3.70 to 3.45) (47).
578 It is uncertain whether ET reduces DBP compared to control in adults who either have
579 moderate and chronic kidney failure, underwent kidney transplantation, cardiovascular
580 disease, type II diabetes, or type II diabetes non-insulin-dependent at short to long-term
581 follow-up because the certainty of the evidence is very low (Table 4).

582 **Mean blood pressure: short term follow-up**

583 Thompson et al., 2019 (48) found that ET may result in clinically important reductions in
584 MBP compared with control in adults with either chronic kidney disease, cardiovascular

585 disease, or type II diabetes up to 12 weeks follow-up (2 RCTs; N=27; MD -12.11 mm Hg,
586 95% CI -15.98 to -8.25; low certainty evidence) (Table 4).

587

588

589

590

591 **Table 4. Summary of findings for the comparison:** Exercise training versus control for systolic and diastolic blood pressure

Exercise training versus control						
Intervention: exercise training						
Comparison: control						
Setting: mixed (home, clinic, and community setting)						
Outcomes	Population	Relative effect (95% CI)	Anticipated absolute effect* (95% CI)		N° of participants (studies)	Certainty of the evidence (GRADE)
			Assumed risk with control	Assumed risk with intervention		
			Systolic blood pressure – short to long term follow-up (4 to 52 weeks)			
Systolic blood pressure (short to long term 4-48 weeks)	Moderate kidney failure Dialysis treatment Kidney transplantation	MD -5.88 (-9.48 to -2.28)	The mean SBP (mm Hg) range was from 132.9 to 153.1	Mean SBP (mm Hg) was 5.88 lower (9.48 lower to 2.28 lower)	347 (8) ^a	⊕⊕⊕⊕ Low ^{1,3}
Systolic blood pressure (short to long term 12-52 weeks)	Chronic kidney disease Cardiovascular disease Type II diabetes	MD -4.33 (-9.04 to 0.38)	Not estimate	Mean SBP (mm Hg) was 4.33 lower (9.04 lower to 0.38 higher)	335 (10) ^b	
Systolic blood pressure (short to long term 8-48 weeks)	Non-insulin-dependent type II diabetes	MD -4.16 (-9.46 to 1.14)	Not estimate	Mean SBP (mm Hg) was 4.16 lower (9.46 lower to 1.14 higher)	127 (4) ^c	
			Systolic blood pressure – short to long term follow-up (4 to 48 weeks)			
Systolic blood pressure (short to long term 4-48 weeks)	Moderate kidney failure Dialysis treatment Kidney transplantation	MD -4.60 (-8.83 to -0.37)	The mean SBP (mm Hg) range was from 132.9 to 153.1	Mean SBP (mm Hg) was 4.60 lower (8.33 lower to 0.37 lower)	211 (5) ^{a#}	⊕⊕⊕⊕ Low ^{3,4}
			Systolic blood pressure – short to long term follow-up (4 to 48 weeks)			
Systolic blood pressure (short to long term 4-48 weeks)	Moderate kidney failure Dialysis treatment Kidney transplantation	MD -0.86 (-7.82 to 6.10)	The mean SBP (mm Hg) range was from 130.8 to 146	Mean SBP (mm Hg) was 0.86 lower (7.82 lower to 6.10 higher)	147 (3) ^{a#}	⊕⊕⊕⊕ Very Low ^{4,5}
			Diastolic blood pressure – short to long term follow-up (4 to 52 weeks)			
Diastolic blood pressure (short to long term 4-48 weeks)	Moderate kidney failure Dialysis treatment Kidney transplantation	MD -2.32 (-4.05 to -0.59)	The mean DBP (mm Hg) range was from 72.8 to 90.6	Mean DBP (mm Hg) was 2.32 lower (4.05 lower to 0.59 lower)	419 (10) ^a	⊕⊕⊕⊕ Very Low ^{1,2}
Diastolic blood pressure (short to long term 12-52 weeks)	Chronic kidney disease Cardiovascular disease Diabetes type 2	MD -1.18 (-4.76 to 2.40)	Not estimable	Mean SBP (mm Hg) was 1.18 lower (4.76 lower to 2.40 higher)	303 (8) ^b	

Diastolic blood pressure (short to long term 8-48 weeks)	Non-insulin-dependent type II diabetes	MD -0.13 (-3.70 to 3.45)	Not estimable	Mean DBP (mm Hg) was 0.13 lower (3.70 lower to 3.45 higher)	78 (3) ^c	
			Diastolic blood pressure – short to long term follow-up (4 to 48 weeks)			
Diastolic blood pressure (short to long term 4-48 weeks)	Moderate kidney failure Dialysis treatment Kidney transplantation	MD -3.98 (-6.05 to -1.90)	The mean DBP (mm Hg) range was from 82 to 90.6	Mean DBP (mm Hg) was 3.98 lower (6.05 lower to 1.90 lower)	254 (6) ^{a#}	⊕⊕⊖⊖ Low ^{3,4}
			Mean blood pressure – short term follow-up (4 to 16 weeks)			
Mean blood pressure (short term up to 12 weeks)	Chronic kidney disease Cardiovascular disease Diabetes type 2	MD -12.11 (-15.98 to -8.25)	Not estimable	Mean MBP (mm Hg) was 12.11 lower (15.98 lower to 8.25 lower)	27 (2) ^b	⊕⊕⊖⊖ Low ^{4,5}

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). CI: Confidence interval; DBP: diastolic blood pressure; ET: exercise training; MD: mean difference; RCT: randomized controlled trial; SBP: systolic blood pressure.

^aHeiwe et al., 2011; ^bThompson et al., 2019; ^cThomas et al., 2006.

^{a#}Heiwe et al., 2011, high intensity ($\geq 60\%$) ET

^{a¶}Heiwe et al., 2011, low intensity ($< 60\%$) ET

¹ Downgraded by one level due to wide confidence intervals (imprecision).

² Downgraded by two levels due to selection bias (random sequence generations and allocation concealment), detection bias (unblinded outcome assessor), incomplete outcome data (attrition bias), and selective reporting (reporting bias).

³ Downgraded by one level due to selection bias (random sequence generations and allocation concealment) and detection bias (unblinded outcome assessor).

⁴ Downgraded by one level due to small sample size (imprecision).

⁵ Downgraded by one level due to selection bias (random sequence generations and allocation concealment), detection bias (unblinded outcome assessor), incomplete outcome data (attrition bias)

593 **Comparison 7: Isometric resistance training versus control**

594 Three reviews studied the effects of IRT on SBP and DBP compared with control groups
595 (36,38,46); one review reported effect data for this intervention on MBP with the same comparison
596 at short-term follow-up (46). The reviews included adults who either are normotensive,
597 prehypertensive, or have high blood pressure (36,38,46). Participants' age ranged from 18 to 80
598 years (36,38,46).

599 **Systolic blood pressure: short term follow-up**

600 Smart et al., 2019 observed a clinically important difference in SBP between IRT and control in
601 normotensive, prehypertensive, or high blood pressure adults at 4 to 12 weeks follow-up (12 RCTs;
602 N=326; MD -7.35 mm Hg, 95% CI -8.95 to -5.75) (46). Fu et al., 2020 confirmed these findings in
603 prehypertensive adults (5 RCTs; N=109; WMD -5.77 mm Hg, 95% CI -10.16 to -1.41) and adults
604 with high blood pressure (5 RCTs; N=109; WMD -5.65 mm Hg, 95% CI -9.87 to -1.47) for this
605 follow-up (36). Similar findings were reported by Herrod et al., 2018 on SBP in normotensive or
606 high blood pressure adults at 4 to 10 weeks follow-up (2 RCTs; N=66; MD -9.14 mm Hg, 95% CI
607 -10.76 to -7.51) (38). Notwithstanding, this body of evidence was rated as of very low quality,
608 which suggests that it is uncertain whether IRT reduces SBP compared to control in adults who
609 either are normotensive or prehypertensive or have high blood pressure levels at short-term follow-
610 up (Table 5).

611 **Diastolic blood pressure: short term follow-up**

612 Smart et al., 2019 reported clinically important differences in DBP between IRT and control in
613 normotensive, prehypertensive, or high blood pressure adults at 4 to 12 weeks follow-up (12 RCTs;
614 N=326; MD -3.29 mm Hg, 95% CI -5.12 to -1.46) (46). These findings were further confirmed by

615 Fu et al. 2020 in prehypertensive adults (5 RCTs; N=109; WMD -4.01 mm Hg, 95% CI -6.93 to -
616 1.07), and adults with high blood pressure (5 RCTs; N=109; WMD -4.00 mm Hg, 95% CI -7.00 to
617 -0.99) for this follow-up (36). Besides, similar findings were reported by Herrod et al., 2018 on
618 DBP in normotensive or high blood pressure adults at short-term follow-up (2 RCTs; N=66; MD -
619 3.01 mm Hg, 95% CI -3.57 to -2.45) (38). Very low quality of evidence suggests that it is uncertain
620 whether IRT reduces DBP compared to control in adults who either are normotensive or
621 prehypertensive, or have high blood pressure levels at short-term follow-up (Table 5).

622 **Mean blood pressure: short term follow-up**

623 Data from Smart et al., 2019 (46) provided very low quality evidence on the effects of IRT on DBP
624 compared to control in adults who either are normotensive or prehypertensive, or have high blood
625 pressure at short-term follow-up (12 RCTs; N=326; MD -4.6 mm Hg, 95% CI -6.18 to -3.09). See
626 Table 5.

627 **Table 5. Summary of findings for the comparison:** Isometric resistance training vs control for systolic, diastolic, and mean blood pressure

628 **Isometric resistance training vs control**

Intervention: isometric resistance training
Comparison: control
Setting: mixed (home and office)

Outcomes	Population	Relative effect (95% CI)	Anticipated absolute effect* (95% CI)		N° of participants (studies)	Certainty of the evidence (GRADE)
			Assumed risk with control	Assumed risk with intervention		
			Systolic blood pressure – short term follow-up (4 to 12 weeks)			
Systolic blood pressure (short term 4-12 weeks)	Normotensive Prehypertensive High blood pressure	MD -7.35 (-8.95 to -5.75)	The mean SBP (mm Hg) range was from -0.4 to 4.02	Mean SBP (mm Hg) was 7.35 lower (8.95 lower to 5.75 lower)	326 (12) ^a	⊕⊕⊕⊕ Very Low ^{1,2}
Systolic blood pressure (short term 8-12 weeks)	Prehypertensive	WMD -5.77 (-10.16 to -1.41)	Not estimable	Mean SBP (mm Hg) was 5.77 lower (10.16 lower to 1.41 lower)	109 (5) ^b	
	High blood pressure	WMD -5.65 (-9.87 to -1.47)	Not estimable	Mean SBP (mm Hg) was 5.65 lower (9.87 lower to 1.47 lower)	109 (5) ^b	
Systolic blood pressure (short term 4-10 weeks)	Normotensive High blood pressure	MD -9.14 (-10.76 to -7.51)	The mean SBP (mm Hg) range was from -8 to 1	Mean SBP (mm Hg) was 9.14 lower (10.76 lower to 7.51 lower)	66 (2) ^c	
			Diastolic blood pressure – short term follow-up (4 to 12 weeks)			
Diastolic blood pressure (short term 4-12 weeks)	Normotensive Prehypertensive High blood pressure	MD -3.29 (-5.12 to -1.46)	The mean DBP (mm Hg) range was from -0.1 to 4.25	Mean DBP (mm Hg) was 3.29 lower (5.12 lower to 1.46 lower)	326 (12) ^a	⊕⊕⊕⊕ Very Low ^{1,3}
Diastolic blood pressure (short term 8-10 weeks)	Prehypertensive	WMD -4.01 (-6.93 to -1.07)	Not estimable	Mean DBP (mm Hg) was 4.01 lower (6.93 lower to 1.07 lower)	109 (5) ^b	
	High blood pressure	WMD -4.00 (-7.00 to -0.99)	Not estimable	Mean DBP (mm Hg) was 4.00 lower (7.00 lower to 0.99 lower)	3 (61) ^b	
Diastolic blood pressure (short term 4-10 weeks)	Normotensive High blood pressure	MD -3.01 (-3.57 to -2.45)	The mean DBP (mm Hg) range was from -3 to 0	Mean DBP (mm Hg) was 3.01 lower (3.57 lower to 2.45 lower)	66 (2) ^c	
			Mean blood pressure – short term follow-up (4 to 12 weeks)			
Mean blood pressure (short term 4-12 weeks)	Normotensive Prehypertensive High blood pressure	MD -4.6 (-6.18 to -3.09)	The mean MBP (mm Hg) range was from -0.12 to 3.33	Mean MBP (mm Hg) was 4.6 lower (6.18 lower to 3.09 lower)	326 (12) ^a	⊕⊕⊕⊕ Very Low ^{3,4}

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). CI: Confidence interval; DBP: diastolic blood pressure; MBP: mean blood pressure; MD: mean difference; RCT: randomized controlled trial; SBP: systolic blood pressure; WMD: Weighted mean difference.

^aSmart et al., 2019; ^bFu et al., 2020; ^cHerrod et al., 2018.

¹ Downgraded by two levels due to selection bias (random sequence generations and allocation concealment), detection bias (unblinded outcome assessor), and publication bias (Funnel plot asymmetry).

² Downgraded by one level due to small sample size (imprecision).

³ Downgraded by one level due to inconsistency (there was statistically significant heterogeneity).

⁴ Downgraded by two levels due to selection bias (allocation concealment), detection bias (unblinded outcome assessor), and publication bias (Funnel plot asymmetry).

629 **Comparison 8: Dynamic Resistance training versus control**

630 One review studied the effects of DRT compared with control on SBP and DBP in adults
631 who either are normotensive or have high blood pressure at short to long-term follow-up.
632 Participants' age ranged from 51 to 70 years (38).

633 **Systolic and diastolic blood pressures: short to long term follow-up**

634 Based on data from Herrod et al., 2018 (38), it is uncertain whether DRT reduces SBP
635 compared to control in adults who either are normotensive or have high blood pressure at
636 short to long-term follow-up (12 RCTs; N=514; MD -5.46 mm Hg, 95% CI -8.61 to -2.31;
637 very low quality evidence). Low quality evidence indicates that DRT may reduce DBP
638 compared to control in adults who either are normotensive or have high blood pressure at 12
639 to 48 weeks follow-up (12 RCTs; N=514; MD -2.02 mm Hg, 95% CI -3.31 to -0.73) (38).
640 See Table 6.

641 **Table 6. Summary of findings for the comparison:** Dynamic resistance training versus control for systolic and diastolic blood pressure.

642

Dynamic resistance training versus control						
Intervention: dynamic resistance training						
Comparison: control						
Setting: mixed (clinic and home)						
Outcomes	Population	Relative effect (95% CI)	Anticipated absolute effect* (95% CI)		N° of participants (studies)	Certainty of the evidence (GRADE)
			Assumed risk with control	Assumed risk with intervention		
			Systolic blood pressure – short to long term follow-up (12 to 48 weeks)			
Systolic blood pressure (short to long term 12-48 weeks)	Normotensive High blood pressure	MD -5.46 (-8.61 to -2.31)	Not estimable	Mean SBP (mm Hg) was 5.46 lower (8.61 lower to 2.31 lower)	514 (12) ^a	⊕⊕⊕⊕ Very Low ^{1,2}
			Diastolic blood pressure – short to long term follow-up (12 to 48 weeks)			
Diastolic blood pressure (short to long term 12 to 48 weeks)	Normotensive High blood pressure	MD -2.02 (-3.31 to -0.73)	Not estimable	Mean DBP (mm Hg) was 2.02 lower (3.31 lower to 0.73 lower)	514 (12) ^a	⊕⊕⊕⊕ Low ¹

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). CI: Confidence interval; DBP: diastolic blood pressure; MD: mean difference; RCT: randomized controlled trial; SBP: systolic blood pressure.

^aHerrod et al., 2018

¹ Downgraded by two levels due to selection bias (random sequence generations and allocation concealment), detection bias (unblinded outcome assessor), incomplete outcome data (attrition bias), and selective reporting (reporting bias)

² Downgraded by one level due to inconsistency (there was statistically significant heterogeneity).

643 **Secondary outcome:**

644 **Adverse events**

645 Eight reviews mentioned adverse events related to the different exercise training modalities
646 (34,35,37,41,43,45,47); however, only four out of the eight reviews reported specific data on
647 adverse events (34,35,41,43), as follows:

- 648 • Lee et al., 2021 show that from 73 included trials, only 21 evaluated adverse events.
649 Of this twenty-one, five reported eight adverse events such as four knee pain, one
650 stress fracture, knee injury, bruised foot, and tripped.
- 651 • Anderson et al., 2017 (34): Two RCTs (20%) reported evidence of no difference in
652 revascularization or recurrent myocardial infarction events between home and centre-
653 based cardiac rehabilitation.
- 654 • Ferrari et al., 2019 (35): Four episodes of either hypotension or muscle pain occurred
655 in one RCT (8%).
- 656 • Qiu et al., 2014 (43): One RCT (8%) reported some cases of mild hypoglycemia.

657 **DISCUSSION**

658 **Summary of main results**

659 The body of evidence on the benefits and harms of exercise training for blood pressure
660 outcomes in adults consists of 17 high-quality systematic reviews, which studied different
661 modalities of exercise training (i.e., AET, DRT, IRT, CT, and ET) in heterogeneous
662 populations (e.g., adults with high blood pressure, type II diabetes mellitus, or renal disease).
663 Overall, the included reviews provided data for 17 comparisons; 8 of those are prioritized
664 due to their relevance in clinical practice guidelines and decision-making. The main findings
665 indicate that when compared to control:

- 666 • Any aerobic training probably results in a large reduction in SBP and DBP in adults
667 with either type II diabetes, metabolic syndrome, end-stage renal disease, or kidney
668 transplantation at short to long-term follow-up (moderate-certainty evidence),
- 669 • Walking aerobic training probably results in a large reduction in either SBP or DBP
670 in adults who either are normotensive, prehypertensive, or have high blood pressure
671 at short to long-term follow-up (moderate-certainty evidence),
- 672 • Walking aerobic training probably results in a large reduction in SBP in normotensive
673 adults at short to long-term follow-up (moderate-certainty evidence),
- 674 • Walking aerobic training probably results in a large reduction in DBP in adults with
675 high blood pressure at short to long-term follow-up (moderate-certainty evidence),
- 676 • Combined training probably results in a large reduction in DBP in adults who either
677 are normotensive, or have high blood pressure, kidney failure, metabolic syndrome,
678 or end-stage renal disease at short to long-term follow-up (moderate-certainty
679 evidence),
- 680 • DRT and IRT may result in little to no difference in either SBP or DBP in adults who
681 either are normotensive, prehypertensive, or high blood pressure levels at different
682 follow-up periods (very low to low-certainty evidence).

683 The remaining comparisons covered different control groups, such as Tai Chi, yoga, or
684 dietary interventions. Like for the main comparisons, our certainty in this evidence varied
685 between low to very low. Eight SRs provided inconclusive evidence about the safety of the
686 exercise interventions

687 **Overall completeness and applicability of evidence**

688 The knowledge base of this overview applies mostly to participants aged 50 to 80 years, with

689 diagnoses like type II diabetes, high blood pressure, renal disease, obesity, coronary disease,
690 acute myocardial infarction, and cardiovascular risk factors (i.e., overweight and/or obesity),
691 as well as either prehypertensive or healthy adults. The included reviews provided incomplete
692 sociodemographic data as well as limited information about key aspects of the exercise
693 training program's implementation, such as rules for starting level and program progression.
694 This last aspect might constrain the applicability of this evidence to clinical practice.

695 To the best of our knowledge, the current overview represents the most comprehensive and
696 detailed synthesis of secondary research in this field. Our in-depth analysis of the certainty
697 of the evidence, sorted by relevant subgroups and follow-up periods, facilitates a well-
698 detailed understanding on the characteristics of the evidence pertaining each comparison
699 together with the description of the caveats in the evidence.

700 **Certainty of the evidence**

701 Overall, there is a low to very low quality of evidence in this overview, owing mostly to
702 limitations in the risk of bias assessment (e.g., insufficient description of methods for random
703 sequence generation), inconsistency (e.g., statistically significant heterogeneity), and
704 imprecision (e.g., wide confidence intervals and/or small sample size). Despite being
705 assessed as high-quality, the included SRs had some limitations in terms of protocol
706 publication, grey literature searching, publication bias assessment, and conflict of interest
707 disclosure. The RCTs included in the SRs had between low and high risk of bias, mostly due
708 to insufficient description of methods for random sequence generation and allocation
709 concealment, blinding of outcome assessor, incomplete outcome data, and selective reporting

710 **Potential biases in the overview process**

711 This overview of systematic reviews was conducted and reported according to the highest

712 methodological standards (13–15). The comprehensive systematic search, as well as the
713 independent and duplicate conduct of the study selection and data extraction processes,
714 constitute methodological strengths. Moreover, the research team comprised exercise science
715 professionals as well as physiotherapists, and experts in evidence synthesis in the area of
716 exercise in non-communicable diseases. Our well-detailed assessment of the certainty of the
717 evidence facilitates further use of this overview for evidence-informed decision-making
718 purposes. Of note, the limited number of RCTs available for some comparisons as well as
719 the presence of important methodological weaknesses reduces our confidence in these
720 findings. The findings for these comparisons should therefore be interpreted with caution,
721 acknowledging the limitations presented in the summary of findings tables.

722 **Agreements and disagreements with other reviews**

723 Numerous systematic reviews on the effects of exercise for blood pressure outcomes have
724 been published in recent years (51–55), whereas tertiary evidence, an overview of reviews,
725 has been less common in the scientific literature. We identified two tertiary syntheses that
726 partially covered our research question (7,56). Our findings align with those reported by El-
727 Kotob et al., 2020 (56), who based on data from one review, found low to very low evidence
728 in favor of DRT compared to control for changes in SBP and DBP in adults with different
729 comorbidities (e.g., cardiovascular disease, type II diabetes mellitus, and mental health) at
730 various follow-up periods. Besides, the authors of this review deemed exercise as a safe
731 intervention. In 2018, Pescatello et al. reported strong evidence favoring different modalities
732 of PA (i.e., aerobic, dynamic resistance, combined) to reduce blood pressure values in
733 normotensive, prehypertensive, and high blood pressure adults (7). Notwithstanding, direct
734 comparisons regarding the results of these previous overviews (7,56)

735 are not appropriate as our overview included a much larger sample of systematic review and
736 covered a more-detailed assessment of the certainty of the evidence.

737 **Implications for practice**

738 This overview provides the most up-to-date evidence synthesis on the effects of exercise
739 training for blood pressure outcomes in adults with or without comorbidities and
740 cardiovascular risk factors. Our findings might be used by public health authorities in the
741 development of community-wide programs, such as community-based exercise programs
742 (16,50), where political will and stakeholder involvement are essential facilitators. The
743 included reviews provided incomplete information on how the exercise training interventions
744 were implemented, which constrains the transferability of our findings into practice. Besides,
745 we believe that academia should ensure all professionals in charge of exercise prescription
746 be taught on the designing, planning, and prioritizing of exercise training interventions. The
747 detailed subgroup analyses in this overview might inform the tailoring of exercise
748 prescription according to the needs of relevant subgroups (e.g., type II diabetes or end-stage
749 renal disease).

750 **Implications for further research**

751 Findings from this overview highlight the need for further well-conducted RCTs in this
752 research field, whose authors should adhere to international reporting guidance when
753 formulating and publishing these studies, such as the Consensus on Exercise Reporting
754 Template (CERT) tool (57), the SPIRIT checklist (58) and the CONSORT checklist (59).
755 The result from the quality appraisal of the included reviews uncovered important caveats
756 (e.g., no protocol registration and incomplete reporting of the search procedures), these can
757 be tackled by adhering to the PRISMA 2020 statement (13,14). Further reviews should also

758 present the assessment of the certainty of the included evidence to facilitate its use in a
759 decision-making context (60). Another limitation to be addressed by further reviews is the
760 description of the outcome prioritization process and consumer involvement, as none of the
761 included reviews provided such information. Cochrane has published comprehensive
762 guidance in this regard (15).

763 **CONCLUSIONS**

764 We found very low to moderate evidence supporting the benefits of exercise training
765 compared with no interventions or placebo for blood pressure outcomes in adults with
766 different comorbidities or risk factors. Scarce safety data were identified. Our certainty in the
767 evidence was constrained due to methodological limitations, inconsistency, and imprecision.
768 Before drawing more solid conclusions, further well-conducted and well-reported
769 randomized controlled trials are warranted in order to strengthen the evidence base
770 underlying this research question.

771 **OTHER INFORMATION**

772 **Abbreviations**

773 AET: Aerobic Training; AMSTAR: the Assessment of Multiple Systematic Reviews; BMI:
774 Body mass index; BP: Blood Pressure; CKD: chronic kidney disease; CFR: cardiorespiratory
775 fitness CT: Combined Training; DBP: Diastolic Blood Pressure; DRT: Dynamic Resistance
776 Training; ERSD: end-stage renal disease in hemodialysis; GRADE: Grading of
777 Recommendations, Assessments, Development and Evaluation; HIIT: High-intensity
778 interval training; IRT: Isometric Resistance Training; MBP: Mean Blood Pressure; MD:
779 Mean difference; Mets: metabolic syndrome; MICT: moderate-intensity continuous training;
780 NICE: National Institute for Health and Care Excellence; OR: odds ratios ORs; PA: Physical

781 activity; PRISMA-P: Preferred Reporting Items for Systematic Review and Meta-Analyses
782 Protocol; PROSPERO: Prospective Register of Systematic Reviews; RCTs: randomized
783 controlled trials; RoB: risk of Bias; SMD: Standardized mean difference; RR: risk ratios,
784 SBP: Systolic Blood Pressure; SET: supervised exercise therapy; WMD: Weighted mean
785 difference.

786 **Acknowledgments**

787 Andrés F. Loaiza-Betancur, Víctor Díaz-López, and Andrés M. Echavarría-Rodríguez are
788 master's students in the academic program of *Maestría en Ciencias del Deporte y la Actividad*
789 *Física* at Universidad de Antioquia.

790 **Authors' contributions**

791 AFL-B and JFM-E conceptualized the idea for this overview. All authors contributed to
792 performing study selection, data extraction, quality appraisal, and assessment of the certainty
793 of the evidence. AFL-B and JFM-E are the guarantors and drafted the manuscript. All authors
794 read and approved the final manuscript.

795 **Funding**

796 No funding is received for this research project.

797 **Availability of data and materials**

798 Not applicable.

799 **Ethics approval and consent to participate**

800 Not applicable.

801 **Competing interests**

802 The authors declare that they have no competing interests.

803 **Author details**

804 ¹Universidad de Antioquia, Medellín, Colombia.

805 ²Universidad San Buenaventura, Medellín, Colombia.

806 ³Universidad de Valencia. Valencia, España.

807 ⁴Fundación Universitaria María Cano, Medellín, Colombia.

808 ⁵Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway.

809 ⁶Facultad de Cultura Física, Deporte y Recreación, Universidad Santo Tomás, Bogotá,
810 Colombia.

811 REFERENCES

- 812 1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global,
813 Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to
814 2015. *J Am Coll Cardiol* [Internet]. 2017 Jul;70(1):1–25. Available from:
815 <https://www.jacc.org/doi/10.1016/j.jacc.2017.04.052>
- 816 2. Zhou B, Bentham J, Di Cesare M, Bixby H, Danaei G, Cowan MJ, et al. Worldwide
817 trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-
818 based measurement studies with 19·1 million participants. *The Lancet*. 2017
819 Jan;389(10064):37–55.
- 820 3. Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The
821 economic burden of cardiovascular disease and hypertension in low- and middle-
822 income countries: A systematic review. *BMC Public Health* [Internet]. 2018
823 Aug;18(1):1–11. Available from:
824 <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-018-5806-x>
- 825 4. Wierzejska E, Giernaś B, Lipiak A, Karasiewicz M, Cofta M, Staszewski R. A global
826 perspective on the costs of hypertension: a systematic review. *Arch Med Sci AMS*
827 [Internet]. 2020 Jan;16(5):1078–1078. Available from: [/pmc/articles/PMC7444692/](https://pubmed.ncbi.nlm.nih.gov/31196460/)
- 828 5. Bakris G, Ali W, Parati G. ACC/AHA Versus ESC/ESH on Hypertension Guidelines:
829 JACC Guideline Comparison. *J Am Coll Cardiol* [Internet]. 2019 Jun;73(23):3018–
830 26. Available from: <https://pubmed.ncbi.nlm.nih.gov/31196460/>
- 831 6. Niemeijer A, Lund H, Stafne SN, Ipsen T, Goldschmidt CL, Jørgensen CT, et al.
832 Adverse events of exercise therapy in randomised controlled trials: a systematic
833 review and meta-analysis. *Br J Sports Med* [Internet]. 2020 Sep;54(18):1073–80.
834 Available from: <https://pubmed.ncbi.nlm.nih.gov/31563884/>
- 835 7. Pescatello LS, Buchner DM, Jakicic JM, Powell KE, Kraus WE, Bloodgood B, et al.
836 Physical Activity to Prevent and Treat Hypertension: A Systematic Review. *Med Sci*
837 *Sports Exerc* [Internet]. 2019 Jun;51(6):1314–23. Available from:
838 <https://pubmed.ncbi.nlm.nih.gov/31095088/>
- 839 8. Smart NA, Howden R, Cornelissen V, Brook R, McGowan C, Millar PJ, et al.
840 Physical Activity to Prevent and Treat Hypertension: A Systematic Review. *Med Sci*

- 841 Sports Exerc [Internet]. 2020 Apr;52(4):1001–2. Available from:
842 <https://pubmed.ncbi.nlm.nih.gov/32175978/>
- 843 9. Hoffmann F, Allers K, Rombey T, Helbach J, Hoffmann A, Mathes T, et al. Nearly 80
844 systematic reviews were published each day: Observational study on trends in
845 epidemiology and reporting over the years 2000–2019. *J Clin Epidemiol* [Internet].
846 2021 Oct;138:1–11. Available from: <https://pubmed.ncbi.nlm.nih.gov/34091022/>
- 847 10. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, et al.
848 Epidemiology and Reporting Characteristics of Systematic Reviews of Biomedical
849 Research: A Cross-Sectional Study. *PLoS Med* [Internet]. 2016 May;13(5). Available
850 from: <https://pubmed.ncbi.nlm.nih.gov/27218655/>
- 851 11. Lunny C, Brennan SE, Reid J, McDonald S, McKenzie JE. Overviews of reviews
852 incompletely report methods for handling overlapping, discordant, and problematic
853 data. *J Clin Epidemiol* [Internet]. 2020 Feb;118:69–85. Available from:
854 <https://pubmed.ncbi.nlm.nih.gov/31606430/>
- 855 12. Pollock M, Fernandes R, Becker L, Pieper D. Chapter V: overviews of reviews.
856 training.cochrane.org [Internet]. Available from:
857 <https://training.cochrane.org/handbook/current/chapter-v>
- 858 13. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
859 PRISMA 2020 explanation and elaboration: updated guidance and exemplars for
860 reporting systematic reviews. *BMJ* [Internet]. 2021 Mar;372:n160–n160. Available
861 from: <http://www.bmj.com/content/372/bmj.n160.abstract>
- 862 14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
863 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
864 *BMJ* [Internet]. 2021 Mar;372:n71–n71. Available from:
865 <http://www.bmj.com/content/372/bmj.n71.abstract>
- 866 15. Higgins J, Thomas J, Chandler J, Cumpston M, Li T. Cochrane handbook for
867 systematic reviews of interventions Version 6.2 (updated February 2021). 2021;
868 Available from:
869 [https://books.google.es/books?hl=es&lr=&id=cTqyDwAAQBAJ&oi=fnd&pg=PR3&dq=Higgins+JPT,+Thomas+J,+Chandler+J,+Cumpston+M,+Li+T,+Page+MJ,+Welch+VA+\(editors\).+Cochrane+Handbook+for+Systematic+Reviews+of+Interventions+version+6.2+\(updated+February+2021\).+Cochrane,+2021.+Available+from+www.training.cochrane.org/handbook.&ots=tvjGw7zFoo&sig=YDf9ZVDL-RPM127y_o0a4V_uhao](https://books.google.es/books?hl=es&lr=&id=cTqyDwAAQBAJ&oi=fnd&pg=PR3&dq=Higgins+JPT,+Thomas+J,+Chandler+J,+Cumpston+M,+Li+T,+Page+MJ,+Welch+VA+(editors).+Cochrane+Handbook+for+Systematic+Reviews+of+Interventions+version+6.2+(updated+February+2021).+Cochrane,+2021.+Available+from+www.training.cochrane.org/handbook.&ots=tvjGw7zFoo&sig=YDf9ZVDL-RPM127y_o0a4V_uhao)
- 875 16. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb
876 C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
877 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood
878 Pressure in Adults: A Report of the American College of Cardiology/American Heart
879 Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018
880 May;71(19):e127–248.

- 881 17. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical
882 fitness: definitions and distinctions for health-related research. *Public Health Rep*
883 [Internet]. 1985 [cited 2022 Jan 18];100(2):126–31. Available from:
884 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1424733/>
- 885 18. Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. Physical activity
886 and exercise for chronic pain in adults: an overview of Cochrane Reviews. *Cochrane*
887 *Database Syst Rev* [Internet]. 2017 Apr 24 [cited 2022 Jan 18];2017(4):CD011279.
888 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461882/>
- 889 19. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World
890 Health Organization 2020 guidelines on physical activity and sedentary behaviour. *Br*
891 *J Sports Med*. 2020 Dec;54(24):1451–62.
- 892 20. Fyfe JJ, Bishop DJ, Stepto NK. Interference between Concurrent Resistance and
893 Endurance Exercise: Molecular Bases and the Role of Individual Training Variables.
894 *Sports Med* [Internet]. 2014 Jun 1 [cited 2022 Jan 18];44(6):743–62. Available from:
895 <https://doi.org/10.1007/s40279-014-0162-1>
- 896 21. Taylor BC, Wilt TJ, Welch HG. Impact of Diastolic and Systolic Blood Pressure on
897 Mortality: Implications for the Definition of “Normal.” *J Gen Intern Med* [Internet].
898 2011 Jul;26(7):685–90. Available from: [http://link.springer.com/10.1007/s11606-011-](http://link.springer.com/10.1007/s11606-011-1660-6)
899 [1660-6](http://link.springer.com/10.1007/s11606-011-1660-6)
- 900 22. NICE (National Institute for Health and Care Excellence). NICE Glossary. 2021;
901 Available from: <https://www.nice.org.uk/Glossary?letter=R>
- 902 23. Valenzuela PL, Carrera-Bastos P, Gálvez BG, Ruiz-Hurtado G, Ordovas JM, Ruilope
903 LM, et al. Lifestyle interventions for the prevention and treatment of hypertension.
904 *Nat Rev Cardiol* [Internet]. 2021 Apr;18(4):251–75. Available from:
905 <http://www.nature.com/articles/s41569-020-00437-9>
- 906 24. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al.
907 Development of AMSTAR: a measurement tool to assess the methodological quality
908 of systematic reviews. *BMC Med Res Methodol* [Internet]. 2007 Feb 15 [cited 2022
909 Jan 18];7(1):10. Available from: <https://doi.org/10.1186/1471-2288-7-10>
- 910 25. Loaiza-Betancur AF, Bedoya EAP, Díaz-López VA, Echavarría-Rodríguez AM,
911 Chulvi-Medrano I, González LEI, et al. Effects Of Exercise Training On Blood
912 Pressure: Protocol For An Overview Of Systematic Reviews. 2021; Available from:
913 <https://osf.io/njd4c/>
- 914 26. MacMahon S, Peto R, Collins R, Godwin J, MacMahon S, Cutler J, et al. Blood
915 pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood
916 pressure: prospective observational studies corrected for the regression dilution bias.
917 *The Lancet* [Internet]. 1990 Mar 31 [cited 2022 Jan 19];335(8692):765–74. Available
918 from: <https://www.sciencedirect.com/science/article/pii/0140673690908789>

- 919 27. Collins R, Peto R, MacMahon S, Godwin J, Qizilbash N, Collins R, et al. Blood
920 pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood
921 pressure: overview of randomised drug trials in their epidemiological context. *The*
922 *Lancet* [Internet]. 1990 Apr 7 [cited 2022 Jan 19];335(8693):827–38. Available from:
923 [https://www.thelancet.com/journals/lancet/article/PII0140-6736\(90\)90944-Z/fulltext](https://www.thelancet.com/journals/lancet/article/PII0140-6736(90)90944-Z/fulltext)
- 924 28. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al. Primary
925 prevention of hypertension: clinical and public health advisory from The National
926 High Blood Pressure Education Program. *JAMA*. 2002 Oct 16;288(15):1882–8.
- 927 29. Bidonde J, Menseses J. The Effect of Interventions for Children Who Have
928 Experienced Violence in Close Relationships: An Overview of Reviews [Internet].
929 Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute
930 of Public Health (NIPH); 2017 [cited 2022 Jan 19]. (NIPH Systematic Reviews).
931 Available from: <http://www.ncbi.nlm.nih.gov/books/NBK482105/>
- 932 30. Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al.
933 Interpreting results and drawing conclusions. In: *Cochrane Handbook for Systematic*
934 *Reviews of Interventions* [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2022 Jan
935 19]. p. 403–31. Available from:
936 <https://onlinelibrary.wiley.com/doi/abs/10.1002/9781119536604.ch15>
- 937 31. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist
938 designed to aid consistency and reproducibility of GRADE assessments: development
939 and pilot validation. *Syst Rev* [Internet]. 2014 Dec;3(1):82–82. Available from:
940 <https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/2046-4053-3-82>
- 941 32. Young HML, March DS, Graham-Brown MPM, Jones AW, Curtis F, Grantham CS,
942 et al. Effects of intradialytic cycling exercise on exercise capacity, quality of life,
943 physical function and cardiovascular measures in adult haemodialysis patients: a
944 systematic review and meta-analysis. *Nephrol Dial Transplant* [Internet]. 2018
945 Aug;33(8):1436–45. Available from:
946 [http://www.epistemonikos.org/documents/157f3d41b8e79f1e53c7fa96be4da7cb30dd4](http://www.epistemonikos.org/documents/157f3d41b8e79f1e53c7fa96be4da7cb30dd4af6)
947 [af6](http://www.epistemonikos.org/documents/157f3d41b8e79f1e53c7fa96be4da7cb30dd4af6)
- 948 33. Scapini KB, Bohlke M, Moraes OA, Rodrigues CG, Inácio JF, Sbruzzi G, et al.
949 Combined training is the most effective training modality to improve aerobic capacity
950 and blood pressure control in people requiring haemodialysis for end-stage renal
951 disease: systematic review and network meta-analysis. *J Physiother* [Internet]. 2019
952 Jan;65(1):4–15. Available from: <https://pubmed.ncbi.nlm.nih.gov/30581137/>
- 953 34. Anderson L, Sharp GA, Norton RJ, Dalal H, Dean SG, Jolly K, et al. Home-based
954 versus centre-based cardiac rehabilitation. *Cochrane Database Syst Rev* [Internet].
955 2017 Jun;2017(10). Available from:
956 [https://www.embase.com/search/results?subaction=viewrecord&id=L617010742&fro](https://www.embase.com/search/results?subaction=viewrecord&id=L617010742&from=export)
957 [m=export](https://www.embase.com/search/results?subaction=viewrecord&id=L617010742&from=export)

- 958 35. Ferrari F, Helal L, Dipp T, Soares D, Soldatelli Â, Mills AL, et al. Intradialytic
959 training in patients with end-stage renal disease: a systematic review and meta-
960 analysis of randomized clinical trials assessing the effects of five different training
961 interventions. *J Nephrol* [Internet]. 2020 Apr;33(2):251–66. Available from:
962 <https://pubmed.ncbi.nlm.nih.gov/31865607/>
- 963 36. Fu J, Liu Y, Zhang L, Zhou L, Li D, Quan H, et al. Nonpharmacologic Interventions
964 for Reducing Blood Pressure in Adults With Prehypertension to Established
965 Hypertension. *J Am Heart Assoc* [Internet]. 2020 Oct;9(19):e016804–e016804.
966 Available from:
967 [http://www.epistemonikos.org/documents/93b5737fa6401f6ac0ed8a66f28f937e3f578](http://www.epistemonikos.org/documents/93b5737fa6401f6ac0ed8a66f28f937e3f578873)
968 873
- 969 37. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease.
970 *Cochrane Database Syst Rev* [Internet]. 2011;(10):CD003236–CD003236. Available
971 from:
972 [http://www.epistemonikos.org/documents/ab91214948e6d26be48a0471f4b91b8895d5](http://www.epistemonikos.org/documents/ab91214948e6d26be48a0471f4b91b8895d53068)
973 3068
- 974 38. Herrod PJJ, Doleman B, Blackwell JEM, O’Boyle F, Williams JP, Lund JN, et al.
975 Exercise and other nonpharmacological strategies to reduce blood pressure in older
976 adults: a systematic review and meta-analysis. *J Am Soc Hypertens* [Internet]. 2018
977 Apr;12(4):248–67. Available from:
978 <https://linkinghub.elsevier.com/retrieve/pii/S1933171118300093>
- 979 39. Jansen SCP, Hoorweg BBN, Hoeks SE, van den Houten MML, Scheltinga MRM,
980 Teijink JAW, et al. A systematic review and meta-analysis of the effects of supervised
981 exercise therapy on modifiable cardiovascular risk factors in intermittent claudication.
982 *J Vasc Surg* [Internet]. 2019;69(4):1293-1308.e2. Available from:
983 [https://www.embase.com/search/results?subaction=viewrecord&id=L2001579520&fr](https://www.embase.com/search/results?subaction=viewrecord&id=L2001579520&from=export)
984 [om=export](https://www.embase.com/search/results?subaction=viewrecord&id=L2001579520&from=export)
- 985 40. Kite C, Lahart IM, Afzal I, Broom DR, Randeve H, Kyrou I, et al. Exercise, or
986 exercise and diet for the management of polycystic ovary syndrome: A systematic
987 review and meta-analysis. *Syst Rev* [Internet]. 2019;8(1). Available from:
988 [https://www.embase.com/search/results?subaction=viewrecord&id=L627106281&fro](https://www.embase.com/search/results?subaction=viewrecord&id=L627106281&from=export)
989 [m=export](https://www.embase.com/search/results?subaction=viewrecord&id=L627106281&from=export)
- 990 41. Lee LL, Mulvaney CA, Wong YKY, Chan ES, Watson MC, Lin HH. Walking for
991 hypertension. *Cochrane Database Syst Rev* [Internet]. 2021 Feb;2021(3). Available
992 from: <http://doi.wiley.com/10.1002/14651858.CD008823.pub2>
- 993 42. Ostman C, Smart NA, Morcos D, Duller A, Ridley W, Jewiss D. The effect of
994 exercise training on clinical outcomes in patients with the metabolic syndrome: a
995 systematic review and meta-analysis. *Cardiovasc Diabetol* [Internet]. 2017
996 Dec;16(1):110–110. Available from:
997 [http://www.epistemonikos.org/documents/4e55ce9a64bf98baf24200796020656dd876](http://www.epistemonikos.org/documents/4e55ce9a64bf98baf24200796020656dd8767d77)
998 7d77

- 999 43. Qiu S, Cai X, Schumann U, Velders M, Sun Z, Steinacker JM. Impact of Walking on
1000 Glycemic Control and Other Cardiovascular Risk Factors in Type 2 Diabetes: A Meta-
1001 Analysis. Manzoli L, editor. PLoS ONE [Internet]. 2014 Oct;9(10):e109767–e109767.
1002 Available from:
1003 [http://www.epistemonikos.org/documents/ee6204d672427e712a6691beee980e6779ae](http://www.epistemonikos.org/documents/ee6204d672427e712a6691beee980e6779ae9c33)
1004 [9c33](http://www.epistemonikos.org/documents/ee6204d672427e712a6691beee980e6779ae9c33)
- 1005 44. Seron P, Lanas F, Pardo Hernandez H, Bonfill Cosp X. Exercise for people with high
1006 cardiovascular risk. Cochrane Database Syst Rev [Internet]. 2014 Aug;(8). Available
1007 from: <http://dx.doi.org/10.1002/14651858.CD009387.pub2>
- 1008 45. Shaw KA, Gennat HC, O'Rourke P, Del Mar C. Exercise for overweight or obesity.
1009 Cochrane Database Syst Rev [Internet]. 2006 Oct;(4). Available from:
1010 [https://www.embase.com/search/results?subaction=viewrecord&id=L46841204&from](https://www.embase.com/search/results?subaction=viewrecord&id=L46841204&from=export)
1011 [=export](https://www.embase.com/search/results?subaction=viewrecord&id=L46841204&from=export)
- 1012 46. Smart NA, Way D, Carlson D, Millar P, McGowan C, Swaine I, et al. Effects of
1013 isometric resistance training on resting blood pressure. J Hypertens [Internet]. 2019
1014 Oct;37(10):1927–38. Available from: <https://pubmed.ncbi.nlm.nih.gov/30889048/>
- 1015 47. Thomas D, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane
1016 Database Syst Rev [Internet]. 2006 Jul;(3):CD002968–CD002968. Available from:
1017 <https://pubmed.ncbi.nlm.nih.gov/16855995/>
- 1018 48. Thompson S, Wiebe N, Padwal RS, Gyenes G, Headley SAE, Radhakrishnan J, et al.
1019 The effect of exercise on blood pressure in chronic kidney disease: A systematic
1020 review and meta-analysis of randomized controlled trials. Reboldi G, editor. PLOS
1021 ONE [Internet]. 2019 Feb;14(2):e0211032–e0211032. Available from:
1022 [https://www.embase.com/search/results?subaction=viewrecord&id=L626249886&fro](https://www.embase.com/search/results?subaction=viewrecord&id=L626249886&from=export)
1023 [m=export](https://www.embase.com/search/results?subaction=viewrecord&id=L626249886&from=export)
- 1024 49. Xie B, Yan X, Cai X, Li J. Effects of High-Intensity Interval Training on Aerobic
1025 Capacity in Cardiac Patients: A Systematic Review with Meta-Analysis. BioMed Res
1026 Int [Internet]. 2017;2017:1–16. Available from:
1027 [https://www.embase.com/search/results?subaction=viewrecord&id=L615076791&fro](https://www.embase.com/search/results?subaction=viewrecord&id=L615076791&from=export)
1028 [m=export](https://www.embase.com/search/results?subaction=viewrecord&id=L615076791&from=export)
- 1029 50. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020
1030 International Society of Hypertension Global Hypertension Practice Guidelines.
1031 Hypertens Dallas Tex 1979. 2020 Jun;75(6):1334–57.
- 1032 51. Loaiza-Betancur AF, Chulvi-Medrano I, Díaz-López VA, Gómez-Tomás C. The
1033 effect of exercise training on blood pressure in menopause and postmenopausal
1034 women: A systematic review of randomized controlled trials. Maturitas [Internet].
1035 2021; Available from:
1036 <https://www.sciencedirect.com/science/article/pii/S037851222100075X>

- 1037 52. Loaiza-Betancur AF, Pérez Bedoya E, Montoya Dávila J, Chulvi-Medrano I. Effect of
1038 Isometric Resistance Training on Blood Pressure Values in a Group of Normotensive
1039 Participants: A Systematic Review and Meta-analysis. *Sports Health Multidiscip*
1040 *Approach* [Internet]. 2020 May;12(3):256–62. Available from:
1041 [http://www.epistemonikos.org/documents/da31543a646b5286ddf30df1debde592ab12](http://www.epistemonikos.org/documents/da31543a646b5286ddf30df1debde592ab12a92c)
1042 [a92c](http://www.epistemonikos.org/documents/da31543a646b5286ddf30df1debde592ab12a92c)
- 1043 53. Loaiza-Betancur AF, Chulvi-Medrano I. Is Low-Intensity Isometric Handgrip
1044 Exercise an Efficient Alternative in Lifestyle Blood Pressure Management? A
1045 Systematic Review. *Sports Health Multidiscip Approach* [Internet]. 2020
1046 Sep;12(5):470–7. Available from:
1047 [http://www.epistemonikos.org/documents/cafd846eae660216204b8832dc46ca3a83d1](http://www.epistemonikos.org/documents/cafd846eae660216204b8832dc46ca3a83d184ed)
1048 [84ed](http://www.epistemonikos.org/documents/cafd846eae660216204b8832dc46ca3a83d184ed)
- 1049 54. Oliver-Martínez PA, Ramos-Campo DJ, Martínez-Aranda LM, Martínez-Rodríguez
1050 A, Rubio-Arias JÁ. Chronic effects and optimal dosage of strength training on SBP
1051 and DBP: a systematic review with meta-analysis. *J Hypertens* [Internet]. 2020
1052 Oct;38(10):1909–18. Available from:
1053 <https://journals.lww.com/10.1097/HJH.0000000000002459>
- 1054 55. Noone C, Leahy J, Morrissey EC, Newell J, Newell M, Dwyer CP, et al. Comparative
1055 efficacy of exercise and anti-hypertensive pharmacological interventions in reducing
1056 blood pressure in people with hypertension: A network meta-analysis. *Eur J Prev*
1057 *Cardiol* [Internet]. 2020 Feb;27(3):247–55. Available from:
1058 <https://pubmed.ncbi.nlm.nih.gov/31615283/>
- 1059 56. El-Kotob R, Ponzano M, Chaput JP, Janssen I, Kho ME, Poitras VJ, et al. Resistance
1060 training and health in adults: an overview of systematic reviews1.
1061 [Httpsdoiorg101139apnm-2020-0245](https://doi.org/10.1139/apnm-2020-0245) [Internet]. 2020; Available from:
1062 <https://cdnsiencepub.com/doi/abs/10.1139/apnm-2020-0245>
- 1063 57. Slade SC, Dionne CE, Underwood M, Buchbinder R. Consensus on Exercise
1064 Reporting Template (CERT): Explanation and Elaboration Statement. *Br J Sports*
1065 *Med* [Internet]. 2016 Dec 1 [cited 2022 Jan 25];50(23):1428–37. Available from:
1066 <https://bjsm.bmj.com/content/50/23/1428>
- 1067 58. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT
1068 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ*
1069 [Internet]. 2013 Jan 9 [cited 2022 Jun 12];346:e7586. Available from:
1070 <https://www.bmj.com/content/346/bmj.e7586>
- 1071 59. Schulz KF, Altman DG, Moher D, the CONSORT Group. CONSORT 2010
1072 Statement: updated guidelines for reporting parallel group randomised trials. *Trials*
1073 [Internet]. 2010 Mar 24 [cited 2022 Jan 25];11(1):32. Available from:
1074 <https://doi.org/10.1186/1745-6215-11-32>

1075 60. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE
1076 guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin
1077 Epidemiol. 2011 Apr;64(4):380-2.

1078